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Epilepsy
Epilepsy is a neurological disease which is characterized by unprovoked recurrent
seizures, during which the brain shows abnormal and excessive neuronal activity.
Causes of epilepsy can be manifold and epilepsy is often distinguished into focal
and generalized epilepsy. In focal epilepsy, seizures are caused by focal pathological
changes, such as cortical malformations or tumors, while in generalized epilepsy, the
seizure threshold is lowered throughout the cortex, often due to genetic defects [1].
A large majority of the patients takes antiepileptic drugs (AEDs) to suppress
epileptic seizures [2]. More than twenty different AEDs are currently available
which can be used in mono-therapy or in combination (poly-therapy). Other treat-
ment options include neurostimulation such as vagal nerve or deep brain stimulation
and the ketogenic diet. Surgical resection of the epileptogenic focus is currently
the only treatment to cure epilepsy, albeit very invasive and only possible in a
subgroup of patients: those with a localized and known epileptic focus [1].
Epilepsy is often accompanied with cognitive and behavioral problems, such
as memory or attentional problems [3, 4]. Cognitive problems might originate in
the epilepsy itself (i.e. the seizures or the underlying neuropathology), but also
medicinal treatment is known to induce cognitive and behavioral side effects [5, 6].
Using validated screening methods, side effects have been reported in 60-90%
of the patients with epilepsy [7]. These side effects are an important factor in
the discontinuation of AED treatment [8]. Cognitive side effects, such as mental
slowing, are among the most reported side effects [2, 9], but the occurrence and
severity vary between the different AED types [10].
MR techniques in epilepsy
Several (imaging) techniques are available to study in vivo the effects of epilepsy
and epileptic seizures on the brain, such as electroencephalography (EEG), positron
emission tomography (PET), and magnetic resonance (MR) imaging and spec-
troscopy [11]. Magnetic resonance encompasses a variety of techniques that employ
nuclear magnetic resonance to assess structural, functional, or chemical properties
of tissue. By applying different settings, various tissue contrasts with different
information can be obtained.
With MR imaging (MRI), magnetic properties of 1H-atoms are manipulated
to acquire images, while with MR spectroscopy (MRS), chemical information (of
organic molecules) is obtained from a local region. MRS enables concentration
measurement of different neurometabolites (Table 1.1). Information about brain
function can for instance be obtained with task-related functional MRI. Functional
i
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Table 1.1. Commonly detected neurometabolites [14, 15]. The exact function of most metabolites is
still not completely understood and metabolites can have other, unknown functions.
Neurometabolite Function Marker for
γ-aminobutyric acid (GABA) Inhibitory neurotransmitter Level of tonic inhibition (i.e.
constant inhibitory activity)
Choline (Cho) Component of cell membranes Neurodegeneration/
inflammation, total mem-
brane content
Creatine (Cr) Storage form of energy (ATP
buffer)
Energy metabolism
Glutamate Excitatory neurotransmitter,
involved in glucose metabolism
Metabolic activity
myo-Inositol (mI) Osmolyte, Involved in cell
growth, storage form of glu-
cose, not well understood
Osmotic stress/edema, neu-
rodegeneration
N-acetyl aspartate (NAA) Osmolyte, not well understood Neuronal density, neuronal in-
tegrity
MRI measures blood oxygen levels, and thereby indirectly brain activity when
performing a task or receiving stimuli. By comparing this activity with and with-
out a task or stimulus, areas involved in this task or stimulus perception can be
distinguished.
Both MRI and MRS are currently being applied in patients with epilepsy. MRI
is commonly applied during clinical diagnosis of patients, for instance to find (struc-
turally visible) epileptogenic lesions [12]. Both MRS and fMRI are mainly used for
research purposes. Clinically, MRS is being applied in the diagnosis of metabolic
syndromes and tumor characterizations [13], while fMRI can be used to map spe-
cific brain functions to aid the pre-surgical planning [12].
Brain connectivity
The human brain consists of more than 1011 neurons and 1014 connections, called
synapses, linking these neurons [16]. If a neuron is active, an action potential
travels through the neuron and when this action potential reaches the synapse,
neurotransmitters are released (Figure 1.1). These neurotransmitters induce a sig-
nal in the connected neuron, which can in- or decrease the probability of an action
potential in that neuron. Several chemical substances may act as neurotransmit-
ters, including glutamate and γ-aminobutyric acid (GABA), which are the most
abundant excitatory and inhibitory neurotransmitters in the central nervous sys-
tem, respectively. Other neurotransmitters are important in several brain diseases
but are less abundant, such as dopamine, which is affected in Parkinson’s disease,
or serotonin, important in mood disorders [16].
i
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Presynaptic neuron 
Postsynaptic neuron 
Neurotransmitter 
(GABA, glutamate) 
Figure 1.1. Basic mechanism in a synapse. If the presynaptic neuron is active, neurotransmitters are
released. Neurotransmitters bind to receptors at the postsynaptic neuron, inducing a signal in that
neuron.
Epilepsy, including focal epilepsy, is hypothesized to be a ‘network disease’, indi-
cating that not one single region is involved in seizure generation and propagation,
but rather that it involves the interplay between different brain regions [17, 18].
Epileptic seizures are hypothesized to result from disbalances within these neuronal
networks, either because of increased (or decreased) excitatory (or inhibitory) neu-
rotransmission, changes in connectivity, or altered neuronal cell properties [1]. AED
treatment targets the dynamic processes that affect this disbalance [19].
Because brain regions are connected, seizure activity might also affect brain
structures distant from the seizure focus, even when no seizure activity is present in
these structures. Altered brain networks in patients with epilepsy can also explain
some of the cognitive problems of these patients, since these networks enable the
integration of information, which is essential for complex brain functions [20].
Advanced MR acquisition techniques and analyses methods have been devel-
oped which enable assessment of brain networks, for instance fMRI. Besides evalu-
ating brain activity, fMRI can also be used to assess functional connectivity [21, 22].
This connectivity is defined as correlated brain activity, i.e. ‘neurons that fire to-
gether, wire together’ [23]. Several studies have shown a disrupted functional con-
nectivity and organization of brain networks in patients with epilepsy [19], which
furthermore appeared to be associated with cognitive decline in epilepsy [21, 22].
However, medication-effects were out of scope in most of these studies, while
AED treatment is also an important cause of cognitive problems in patients with
epilepsy [5]. In the first part of this thesis, we therefore focused on these medication
effects.
i
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Aim and outline of this thesis
The aim of this thesis was to further assess associations of brain connectivity and
cognitive problems in epilepsy. Therefore, two goals were formulated:
1. To identify neuronal substrates of cognitive side effects of antiepileptic drugs
using magnetic resonance;
2. To explore and evaluate novel MR techniques that may give new insights into
epilepsy.
The first, clinical question is described in the first part of this thesis. In Chap-
ter 2, a literature study is presented that elaborates on AEDs in relationship to
MR imaging: what are the problems with these drugs, and which possibilities can
MR provide to give insights in these problems? Chapter 3 and 4 present the results
of an MR study we performed to assess associations between AED use, cognitive
problems, and MR biomarkers in patients with chronic epilepsy. In Chapter 3,
associations with neurotransmitter levels measured with MRS are described, while
Chapter 4 describes the associations with functional brain networks measures.
The second part consists of studies of a more methodological nature. Chapter 5
describes and compares two commonly applied MRS methods to measure brain
glutamate levels: PRESS and MEGA-PRESS. This chapter presents the accuracy
(tested in a phantom experiment), repeatability (evaluated in human participants)
and the concordance between the methods (also tested in human participants). In
Chapter 6, an ultra-high-field MRS pilot study is described that assesses the spatial
coherence between local neurotransmitter concentrations in both healthy volunteers
and patients with epilepsy. This chapter presents the concept of ‘neurotransmitter
networks’, a new method to study brain connectivity on the basis of spatial relations
in neurontransmitter concentration distributions.
Finally, all results are summarized and discussed in Chapter 7. This chapter
also includes recommendations for further research and is finalized with a general
conclusion.
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Metabolic and functional MR biomarkers of
antiepileptic drug effectiveness
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Abstract
As a large number of patients with epilepsy do not respond favorably to antiepilep-
tic drugs (AEDs), a better understanding of treatment failure and the cause of
adverse side effects is required. The working mechanisms of AEDs also alter neu-
rotransmitter concentrations and brain activity, which can be measured using MR
spectroscopy and functional MR imaging, respectively. This review presents an
overview of clinical research of MR spectroscopy and functional MR imaging stud-
ies to the effects of AEDs on the brain. Despite the scarcity of studies associating
MR findings to the effectiveness of AEDs, the current research shows clear poten-
tial regarding this matter. Several GABAergic AEDs have been shown to increase
the GABA concentration, which was related to seizure reductions, while language
problems due to topiramate have been associated with altered activation patterns
measured with functional MR imaging. MR spectroscopy and functional MR imag-
ing provide biomarkers that may predict individual treatment outcomes, and enable
the assessment of mechanisms of treatment failure and cognitive side effects.
i
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Introduction
Despite the introduction of several antiepileptic drugs (AEDs) in recent decades, a
large number of patients with epilepsy do not respond favorably to AEDs. Ideally,
AED usage results in complete seizure freedom, without any unwanted side effects.
However, 20-30% of the patients are drug resistant (or, synonymous, medically
refractory), i.e. they do not reach seizure freedom after two adequately chosen,
dosed and tolerated AEDs [1]. Furthermore, many patients suffer from unwanted
side effects, even though the newer generation AEDs is suggested by pharmaceuti-
cal companies to have a more beneficial tolerability profile. Today, approximately
10-40% of the patients with epilepsy report side effects spontaneously or in (un-
structured) interviews, while 60-90% of patients have been reported to suffer from
side effects using validated screening methods [2]. The low effectiveness, i.e. the
low combined efficacy and tolerability, results in early treatment discontinuation,
high disease burden, and increased health care costs [2, 3]. Considering the need
for improvement of the effectiveness, a better understanding of the mechanisms
of drug resistance and the cause of side effects is highly desired. This knowledge
might, in future, aid the realization of an objective, tailored choice of a specific
AED in the individual patient.
Knowledge of the in vivo working mechanisms of AEDs is essential to under-
stand drug resistance and side effects. Currently, most AEDs are discovered us-
ing animal screening models, in which the anticonvulsant effect of a compound is
tested, prior to the exploration of the precise mechanisms of action [1, 4]. An-
imal models are used to test for efficacy [1] and side effects [5]. The molecular
mechanisms of action are assessed at a later stage using in vitro research, including
studies in neuronal cell cultures, patch-clamp measurements, and biochemistry [6].
These studies have resulted in some basic understanding of the different molecu-
lar mechanisms of the available AEDs. However, it still remains difficult to relate
these mechanisms of action to the anticonvulsant effect of an AED in patients,
mainly because the anticonvulsant effect is also influenced by the pharmacokinetic
properties of the compound, such as its ability to cross the blood brain barrier or
its metabolism [4, 7]. Furthermore, the complexity of the brain limits a straight-
forward translation of in vitro effects of isolated neuronal cells to in vivo effects.
Finally, in vitro or animal studies cannot completely assess potential side effects
on cognition, which can only present themselves after administration in human
subjects. Therefore, there is a need for alternative techniques that can assess the
effects of AEDs on human brains.
Clinically, magnetic resonance imaging (MRI) is commonly used to provide
anatomical information. These anatomical scans are also applied to assess effects
i
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of AEDs on for instance brain volume or cortical thickness [8, 9]. However, there
are also MR techniques available that provide information beyond the anatomy,
such as metabolism and function, which expectedly are more sensitive to AED
treatment. MR spectroscopy (MRS) enables in vivo measurements of neurotrans-
mitter and other brain metabolite concentrations, and can therefore be employed to
gather insight in the metabolism of AEDs [10, 11]. Another technique is functional
MRI (fMRI), which can provide a measure of drug effects on brain activity [12].
These MRI assessments are noninvasive, which makes them suitable for repeated
measurements, as no contrast agents or ionizing radiation are necessary, in con-
trast to other imaging techniques such as computed tomography (CT) or positron
emission tomography (PET).
An overview of the previous MRS and fMRI studies to the effects of AEDs on
the brain is presented in this review. These MR techniques are sensitive to brain
metabolism and function, respectively, which are both directly related to the AED
mechanisms of action. Special attention is paid to the possible relation of MR
measures with drug resistance and central nervous system (CNS) mediated side
effects of AEDs.
Methods
A literature study was performed in Medline/PubMed on August 7, 2015, using the
Medical Subject Headings (MeSH) ‘anticonvulsants’, ‘Magnetic Resonance Spec-
troscopy’ and the terms ‘functional MRI’ or ‘fMRI’ and ‘treatment failure’. Ad-
ditionally, separate searches were performed per individual AED (the considered
AEDs are listed in Table 2.1).Furthermore, relevant references from the reviewed
articles are included. Only articles written in English and performed in human sub-
jects are considered. The abstracts of the resulting articles were screened to select
only the relevant articles, i.e. articles describing effects of AEDs detectable with
MRI, or relating MRI outcomes to seizure reduction or side effects. Studies de-
scribing the effects of AEDs in patients with other types of disorders than epilepsy
were omitted, because of potential differences in working mechanisms in different
diseases, and unknown effects of comorbidities. Studies comparing patients with
epilepsy using AEDs to healthy controls not using these AEDs were also omitted,
because the effect of the epilepsy itself and drug use cannot be distinguished in
these studies.
i
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Table 2.1. Molecular targets of anti-epileptic drugs [13–17].
Voltage-gated ion channelsa Neurotransmitter systemsa
Benzodiazepines: GABA system
Clobazam
Clonazepam
Midazolam
Diazepam
Carbamazepine Na+
Ethosuximide (Na+), Ca +2
Felbamate Na+, Ca +2 GABA system,
glutamate receptors
Gabapentin (Na+, Ca +2 ) GABA system
Lacosamide (Na+) Glutamate receptors
Lamotrigine Na+, (Ca +2 )
Levetiracetam Ca +2 (GABA system,
glutamate receptors)
Oxcarbazepine Na+, (Ca +2 , K+)
Phenobarbital Ca +2 GABA system,
(glutamate receptors)
Phenytoin Na+
Pregabalin Ca +2
Retigabine K+ GABA system
Stiripentol GABA system
Tiagabine GABA system
Topiramate Na+, Ca +2 GABA system,
glutamate receptors
Valproate (Na+, Ca +2 ) GABA system,
glutamate receptors
Vigabatrin GABA system
Zonisamide Na+, Ca +2
aNot all molecular mechanisms are well understood; possible molecular targets are displayed between
parentheses.
Pharmacodynamic and pharmacokinetic mechanisms of action
Epileptic seizures are characterized by excessive, synchronal neuronal activity in
the brain. AEDs, ideally, suppress this activity via several distinct mechanisms,
which can be divided into three main categories: 1) Modulation of the voltage-
gated ion channels, i.e. of the sodium or calcium channels, and, less common, of
the potassium channels. This modulation can result in a more stable membrane
potential, reduced release of neurotransmitters, and a reduction in seizure spread.
The exact effects of this modulation depend on the specific channel type. 2) Eleva-
tion of the seizure threshold by targeting the γ-aminobutyric acid (GABA) system.
The GABA system can be affected by two mechanisms: by increasing the sensi-
tivity of the GABAA receptors or by augmenting the GABA concentration. 3)
Reduction of the excitatory neurotransmission. AEDs with the latter mechanism
i
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function as antagonists of the glutamate receptors [15, 17]. Several AEDs combine
different mechanisms, and the mechanisms are not completely understood for all
AEDs (Table 2.1).
In addition to these pharmacodynamic mechanisms, pharmacokinetic properties
contribute greatly to the positive and negative effects of AEDs. Pharmacokinetic
properties include the absorption, distribution, metabolism, and excretion of a
compound. These factors can differ among different users and with different AEDs,
and complicate the prediction of the efficacy and the tolerability in individual
patients [18].
Unfortunately, the mechanisms that aim to suppress epileptic seizures can also
affect normal brain activity. Modifying these mechanisms can also induce side ef-
fects. These CNS mediated side effects include sedation, coordination disturbances,
cognitive difficulties, and behavioral problems. Although the probability and sever-
ity of these side effects depend on the AED type, several of these events are quite
similar among the different AEDs [2]. Also several non-CNS mediated side effects
can occur with the use of AEDs, which might result from pharmacokinetic proper-
ties, interaction effects, or effects on other organ systems and the immune system
(allergic reactions) [2, 3].
Treatment failure is defined as the appearance of recurrent seizures after ade-
quate intervention [19]. Treatment failure in previous AEDs is a strong indicator of
treatment failure for new AEDs: While approximately 62% of the patients became
seizure free after the first, adequately chosen AED, only 17% of the patients became
seizure free after failure of two to five adequately chosen AEDs in a cohort study
of 478 patients with newly administered AEDs and various epilepsy types [20].
The mechanisms of treatment failure and drug resistance are also still largely un-
known, and both pharmacodynamic and pharmacokinetic properties are likely to
be involved in these mechanisms. Several hypotheses have been formulated which
explain treatment failure in patients with epilepsy, of which the transporter and the
target hypothesis are most popular. The transporter hypothesis argues that AEDs
cannot sufficiently penetrate the epileptogenic brain tissue, as a result of increased
expression of eﬄux transporters in the blood-brain barrier. According to the target
hypothesis, AEDs are able to reach the ion channels or receptors, but cannot ex-
ert their function due to structural and/or functional alterations of these targets.
A combination of the above listed hypotheses and other mechanisms (including
inflammatory, epigenetic, and also unknown pathways) most likely cooperate in
some way to drug resistance in epilepsy [1, 21].
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Figure 2.1. A. Example of magnetic resonance spectrum measured in the occipital lobe of a healthy
human. The concentrations of NAA, creatine and the choline-containing compounds are relatively
high in the brain, resulting in large resonance peaks. Although GABA, glutamate and glutamine are
also abundant in the brain, their resonance peaks are much smaller because of spin-spin interactions.
The 4 CH2 group of GABA has approximately the same resonance frequency as the N(CH3) group of
creatine and is only measurable using advanced acquisition or analysis methods [22]. The same holds
for glutamate and glutamine. B. Estimations by LCModel [23] of the contribution of single molecules to
the spectrum displayed in A. Cho: choline-containing compounds; Cr: creatine; GABA: γ-aminobutyric
acid; Glu: glutamate; Gln: glutamine; NAA: N-acetyl-aspartate; ppm: parts per million.
Magnetic resonance spectroscopy
AEDs exert their anticonvulsant properties by affecting the excitatory and in-
hibitory neurotransmitter systems. Effects on the GABA and glutamate concen-
trations can be measured directly in vivo using 1H-MRS (proton MRS). The merit
of 1H-MRS is based on the shielding effect of the chemical environment of protons,
which causes a small shift in resonance frequency. 1H-MRS results in a spectrum
with peaks at different resonance frequencies, characteristic for different molecule
groups (Figure 2.1). The area underneath these peaks is proportional to the concen-
tration of the molecule. Whether it is possible to measure a particular metabolite
depends on its concentration in the brain, spectral overlap with other metabolites,
and spin-spin interactions, which can result in lower resonance peaks [10].
GABA and glutamate both are subject to spectral overlap and spin-spin in-
teractions (Figure 2.1). Special editing techniques or 2D 1H-MRS are commonly
used to resolve this problem [10, 24]. These techniques enable a reliable estimation
of the concentration of the metabolites [24]. Due to their overlapping resonances,
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the glutamate and glutamine concentrations are frequently combined, resulting in
a so-called ‘Glx’ concentration. Other metabolites which are commonly measured
using 1H-MRS include N-acetyl aspartate (NAA), creatine or choline-containing
compounds. The functions of these metabolites are elaborately discussed else-
where [22, 25].
Several AEDs with a GABAergic mechanism of action have been shown to
elevate GABA concentrations in the brain, including vigabatrin (VGB) [26–32],
topiramate (TPM) [33–36] and gabapentin (GBP) [34, 37–39] (Figure 2.2). El-
evated GABA concentrations were already detectable within hours after intake
of a single dose and also appeared during chronic VGB, TPM and GBP use, al-
though no effects of a single low dose GBP on the GABA concentration were found
by Preuss et al. [40]. There is a linear relation between the VGB dosage and the
resulting GABA concentration. However, with high VGB dosages, the GABA con-
centration does not increase any further and reaches a plateau [41]. The GABA
concentration was related to seizure reduction in patients with focal epilepsy with
VGB [42] and GBP use [39]. Moreover, a relation was found between seizure
reduction and the GABA concentration before and during VGB treatment in pa-
tients with poorly controlled focal epilepsy [43]. Patients with focal epilepsy with
complete seizure control had a lower baseline GABA concentration in the epileptic
hemisphere, compared with the non-epileptic hemisphere, and a significant increase
of GABA. However, patients with no VGB-induced seizure reduction did not re-
veal concentration differences between the hemispheres or a significant increase
in GABA concentration. The pretherapeutic concentration differences between
the hemispheres correlated with the seizure reduction during VGB treatment [44].
These results suggest a causal relation between GABAergic mechanisms of action,
the increase in GABA concentration, and seizure reduction. However, this causal
link cannot be proven using these radiological techniques in human studies.
In contrast to these results, no effects of a single dose of tiagabine (TGB)
on the GABA concentration were found in healthy participants by Myers et al.
[45], although TGB is an AED with a solely GABAergic mechanism of action as
well. Generalizations across the different AEDs should be considered with caution,
because the mechanism of action each individual AED is unique even for chemically
related AEDs.
The effects of levetiracetam (LEV) on the GABA concentration are not clear.
The mechanisms of action of LEV are not completely understood but according
to literature it has probably multiple mechanisms of action, including a GABAer-
gic mechanism [15]. While one study showed a significant increase in the GABA
concentration after LEV use in patients with focal epilepsy who had a seizure re-
duction [46], another study failed to show effects on the GABA concentration in
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Figure 2.2. Graphs illustrating the effect of topiramate on the GABA concentration, as measured
with MR spectroscopy. A. Serial GABA spectra of a patient with epilepsy before and after use of
topiramate. This spectrum, measured using a special editing technique, shows an increase in GABA
concentration in an individual patient [Reprinted from Petroff et al. [35]]. B. Time changes of the
GABA concentrations (dashed line) and serum topiramate (TPM, solid line) levels before and during
TPM use [Reprinted from Kuzniecky et al. [34]]. The GABA concentration is significantly increased
compared with the baseline concentration during TPM use. ∗: p<0.001, ∗∗: p<0.006, ∗∗∗: p<0.002,
∗∗∗∗: p<0.005. GABA: γ-aminobutyric acid; ppm: parts per million, h: hours, w: weeks
healthy participants [47]. Besides the difference in participants (patients with focal
epilepsy versus healthy people), this difference might be explained by the timing of
the measurements: the MRS measurements were performed before and 2-6 weeks
after initiation of LEV treatment in the patients with epilepsy, while the measure-
ments were performed before, at 3 and at 6 hours after a single dose of LEV in
the healthy participants. The effect on the GABA concentration of AEDs without
a known GABAergic mechanism of action is rarely assessed. However, elevated
GABA concentrations are shown in healthy participants with lamotrigine (LTG)
use, albeit only after four weeks use and not directly after a single dose or after
2 weeks of LTG usage, implying that the GABA concentration is increased by
indirect effects of LTG [34].
Also the effects of AEDs on the homocarnosine and pyrrolidine metabolites were
assessed. These metabolites are precursors of GABA and have been suggested to
have anticonvulsant properties themselves [48]. The homocarnosine and pyrrolidine
concentrations were shown to increase with the use of TPM [35, 36], VGB [28,
49] or GBP [38]. The authors suggested that homocarnosine (and not GABA) is
associated with seizure reduction in patients with focal epilepsy using TPM and
GBP [50], using VGB [49], or in a group of patients with focal epilepsy or juvenile
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myoclonic epilepsy using valproate (VPA) or LTG [51].
The effects of AEDs on the glutamate concentration are also not clear. Arti-
cles assessing the effects of GBP [37, 40], benzodiazepines [52, 53], VPA [54], or
TPM [55] on the glutamate, glutamine, or Glx concentration failed to show con-
sistent results. In contrast to the GABAergic mechanisms, AEDs do not alter the
glutamate concentrations directly, but rather decrease the sensitivity of the glu-
tamate receptors. The glutamate concentration might be decreased through the
negative modulation of the voltage-gated channels, which are affected by most of
the AEDs.
Indirectly, AEDs might also affect the concentrations of other metabolites.
Campos et al. [56] showed decreased NAA concentrations in patients with focal
epilepsy who did not respond to their AED treatment compared with responders
one to two years after initiation of AED therapy. As the NAA concentration is
generally associated with neuronal density or integrity, these results suggest that
treatment failure can be associated with neuronal damage. The choline concen-
tration did not differ between these responder groups. Furthermore, patients with
various types of epilepsy using VPA showed reduced myo-inositol concentrations
compared with patients taking other AEDs, but similar NAA and creatine con-
centrations [54, 57]. The authors argue that the myoinositol reductions are not
likely to be related to the antiepileptic efficacy of VPA. In healthy participants,
no changes in the NAA or choline concentrations were measured after GBP in-
take [40], and also lorazepam intake did not affect the NAA, creatine, myoinositol,
or trimethylamine concentrations [52].
Effects on neurotransmitter concentrations can also be measured in animal mod-
els. However, the results of animal studies do not always correspond to human stud-
ies. For instance, the effect of TPM on the GABA concentration was not predicted
by animal models [35]. Moreover, homocarnosine concentrations are much lower in
rodents compared to humans, while homocarnosine is suggested to be involved in
the anticonvulsant mechanisms [35]. The results of Kuzniecky et al. [34], showing
long-term elevations of GABA after LTG use, illustrate that also AEDs without
a known GABAergic mechanism can (indirectly) alter the GABA concentrations.
This necessitates human in vivo measurements.
Functional MRI
fMRI uses the blood oxygen level dependent (BOLD) effect to indirectly measure
brain activity. By comparing the BOLD signal of a baseline condition to a situa-
tion with a task, an activity measure for the brain areas involved in this task can
be obtained [12]. BOLD measurements can also be performed without a certain
i
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task. This so-called resting state fMRI measures the spontaneous fluctuations of
the ongoing neural signaling. The spontaneous fluctuations show correlations be-
tween several distinct brain areas, and these correlations are assumed to reflect
intrinsic functional connections. Advanced analysis techniques, such as indepen-
dent component analysis or graph theory, can be applied to assess the functional
brain connectivity [58].
It is plausible to assume that AEDs, by suppressing the epileptiform activity,
also affect normal brain activity and thereby the BOLD signal. Different brain
areas might be more susceptible to AED actions compared with other regions, as
AEDs exert their function on specific receptors which might be more prominent
in specific brain areas than other. fMRI can be used to identify these altered
activation patterns in relation to CNS-mediated side effects or treatment failure.
Several studies employing task fMRI indeed show that AEDs have different ef-
fects on brain activation patterns in healthy participants [59–65] or in patients with
drug resistant temporal lobe epilepsy [66]. These effects vary among AEDs [67, 68]
and depend on the specific task performed during the measurements [69]. While
AEDs mainly attenuate the activation patterns, as can be expected from their
mechanisms of action, also enhanced activation during AED use has been re-
ported [70]. This seemingly contradictory result could be an indirect effect of
attenuated activation in other brain areas, or result directly from AED mecha-
nisms, as a computer simulation showed that modulation of the sodium channels
by phenytoin or carbamazepine can also lead to increased excitation [71].
Using graph analysis, a lower hubness (the presence of hyperconnected nodes
that connect distant parts of the brain) was found in patients with temporal lobe
epilepsy using carbamazepine or oxcarbazepine compared with patients using other
AEDs, implying a less efficient organization [72]. Relating these findings to anticon-
vulsant mechanisms or the development of CNS mediated side effects was outside
the scope of these articles.
Other studies assessed associations between cognitive side effects, brain acti-
vation and TPM, which induces cognitive side effects including language distur-
bances [14]. In a study comparing patients with cryptogenic (i.e. with unknown
cause) focal drug resistant epilepsy using TPM with patients using other AEDs,
several language areas appeared to be significantly underactivated during a lan-
guage task in the patients using TPM (Figure 2.3). Decreased activation in these
areas was also correlated to the language problems [73]. Similar results were found
in patients with migraine treated with TPM [74]. Another study found compa-
rable differences in brain activation between patients with temporal lobe epilepsy
using TPM and patients using other AEDs, although the observed differences also
depended on the lateralization of the epileptic focus [75]. Besides effects in lan-
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Figure 2.3. Activations maps of a group of patients with cryptogenic focal epilepsy using topiramate
(TPM, n=5, right) versus patients using other AEDs (n=10), obtained using a covert word generation
paradigm [Reprinted from Jansen et al. [73]]. These activation maps show a significantly underac-
tivation in the language areas in patients using topiramate compared with other patients. L: left.
guage areas, patients with frontal lobe epilepsy taking TPM showed a reduced
deactivation of the default mode network [76]. The default mode network consists
of functionally connected brain areas which are active during rest, but deactivate
during tasks. Appropriate deactivation of this network is considered necessary for
correct task performance.
In contrast to TPM, LEV does not negatively affect cognitive abilities, and is
even suggested to improve cognitive function [14]. Patients with temporal lobe
epilepsy taking LEV showed more deactivations in the ipsilateral mesial tempo-
ral structures compared with patients using other AEDs during working memory
tasks [77]. Stronger deactivation in these structures is commonly associated with
improved functioning [77]. Whether this reduction was also associated with better
cognitive functioning in this study was not reported.
Treatment failure is hypothesized to be caused by alterations of the blood-brain
barrier or the molecular targets of the AEDs [1]. Because of these alterations, AEDs
cannot exert their function in the epileptogenic brain tissue. However, the location
of this epileptogenic brain tissue varies largely between patients, while fMRI is
mainly employed to assess the susceptibility of distinct brain areas to the effects of
AEDs. In case fMRI experiments are combined with knowledge about the epileptic
focus, fMRI might provide new information about mechanisms of action.
Interestingly, Kay et al. [78] also showed associations between treatment resis-
tance and functional connectivity. Patients with idiopathic generalized epilepsy
resistant to AEDs showed a reduced connectivity in the default mode network
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compared with patients who did show a seizure reduction. Whether this is a con-
sequence of the drug resistance (i.e. the continuing seizures) or is preceding the
drug resistance remains unknown.
Limitations
The application of MR techniques in AED treatment is still in its infancy, and
several research gaps need to be bridged before these techniques can prove their
clinical utility. Currently, the number of MR studies assessing the effects of AEDs
is limited, and only a few studies relate MR outcomes to either seizure reduction
or CNS mediated side effects. Furthermore, many of the included articles have low
participant numbers and have to deal with practical constraints such as polytherapy
and possible confounding effects of the epilepsy itself, limiting the quality of these
studies.
Beside these general study limitations, the different MR techniques also have
some limitations. The interpretation of 1H-MRS findings is currently debated [79,
80]. 1H-MRS measures all available neurotransmitters: both synaptically and ex-
trasynaptically (presynaptic terminals, synaptic vesicles or neurotransmitter up-
take mechanisms), and it is not known where and how these neurotransmitters act
precisely [79]. 1H-MRS is also only able to measure the neurotransmitter concen-
trations but not the receptor sensitivity, while this sensitivity is affected by AEDs
in particular and could be crucial for effectiveness. Furthermore, the neurotrans-
mitter concentrations are usually measured in a large, single voxel located in the
occipital brain regions, whereas the majority of the side effects concerns functions
dependent on other brain regions. The use of smaller voxels or voxels located in
those other brain areas is limited by the signal-to-noise ratio (SNR) and magnetic
field inhomogeneities.
Moreover, most AEDs exert their anticonvulsant activity using several mech-
anisms, and the interaction between these mechanisms is largely unknown. Only
analyzing the effects of the AEDs on the GABA concentration might therefore be
too simplistic. Although currently not many effects of AEDs on the glutamate
concentrations are shown, it is recommended to measure this concentration as well
to have an indication of the balance between the main inhibitory and excitatory
mechanisms.
No general conclusions can be drawn about the specific effects of AEDs on
the brain activity. Most fMRI studies are performed with specific tasks, and the
results of these studies are difficult to generalize because of their task-dependency.
Another drawback of fMRI studies is that some AEDs might affect the blood flow
and thereby the BOLD signal, irrespective of their antiepileptic effect. These effects
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should be considered in future fMRI studies to AEDs. For instance, fMRI studies
can be combined with arterial spin labeling measurements, to measure the blood
flow [81].
Perspectives
Despite these limitations, both MRS and fMRI results show potential promising
applications in future AED research. The suggested relation between GABAergic
mechanisms of action, the GABA concentration measured using MRS, and seizure
reduction implies several possibilities. First, the GABA concentration can be used
as a biomarker for seizure reduction, enabling an earlier indication of treatment
failure than clinical evaluation. Furthermore, MRS might provide insights in the
development of CNS mediated side effects. The mechanisms responsible for this
development still remain largely unknown, although some studies hypothesize that
GABAergic mechanisms are involved [5, 73]. By providing a tool to measure the
effects of these GABAergic mechanisms, MRS might indicate whether these mech-
anisms can indeed be associated with CNS mediated side effects. Therefore, MRS
might provide valuable information for the selection of the most suitable AED,
or exclusion of AEDs which are less suitable, prior to or soon after initiation of
treatment. These potential utilities can only be proven after future suitable studies.
fMRI might be employed to pinpoint the neuronal substrate of the side effects.
Abnormal activation patterns could possibly explain in part why some patients
experience more and others less CNS mediated side effects, and might even predict
this for individual patients. Furthermore, the occurrence of side effects might be
predicted for new antiepileptic compounds, if it is known how AED effects on brain
activity are associated with these side effects.
New studies should focus on the usefulness of these MR techniques for different
types of epilepsy, especially when relating treatment failure to MR outcome. Treat-
ment failure is more common in specific epilepsy syndromes (Ohtahara syndrome,
early myoclonic encephalopathy, West syndrome, Dravet syndrome, or Lennox-
Gastaut syndrome) and underlying etiologies (hippocampal sclerosis, cortical dys-
plasia, hemorrhage) [82], and the mechanisms of drug resistance might depend on
the specific brain pathology [21]. MRS and fMRI might also be employed to assess
the effects of other epilepsy treatments, such as the ketogenic diet, and compare
these to AED effects on brain metabolite concentrations or activation patterns [83].
Novel, and more advanced MR technologies offer new opportunities to overcome
many of the current limitations. With the use of higher magnetic field strengths, the
SNR of MRS can be increased. Smaller voxels, frontally located voxels, and even
multivoxel MRS becomes feasible with 7 Tesla MR studies (see for instance Pan
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et al. [84]). These studies can increase the knowledge of regional effects of AEDs
on the neurotransmitter concentration. Besides 1H-MRS, also 13C-MRS can be
employed. This method enables the assessment of neurotransmitter cycling and
human brain energetics, although 13C-MRS is less accessible than 1H-MRS due to
the low natural abundance of 13C and the need for labeled compounds and special
hardware [85]. Furthermore, while MRS does not measure the receptor sensitivity,
multimodal studies combining PET and MRS enable assessments of both receptor
sensitivity and neurotransmitter concentrations [32]. Finally, contrast-enhanced
MRI allows for the assessment of the blood-brain barrier integrity, which could be
an important feature of treatment failure [86].
The advanced analysis methods for fMRI data provide opportunities to assess
the functional brain connectivity. This functional brain connectivity might be more
related to cognition than brain activity patterns [87], and therefore more relevant
to assess especially cognitive side effects than task related activity analysis. These
methods are often employed in combination with resting state fMRI, thereby also
omitting the task-dependence of the results [58].
To conclude, MR techniques provide several unique possibilities to assess neu-
ronal substrates of the effectiveness of AEDs, which might be employed for future
individualized patients care. These possibilities are supported by the technologi-
cal improvements of the last decade, which open new possibilities to apply fMRI
and MRS to assess AED mechanisms and effects. However, future studies are still
necessary to investigate the potential of the different MR techniques to provide
biomarkers, to predict treatment outcome or to assess the mechanisms of treat-
ment failure and side effects.
References
[1] W. Loscher, H. Klitgaard, R. E. Twyman, and D. Schmidt. New avenues for anti-epileptic drug
discovery and development. Nat Rev Drug Discov, 12(10):757–76, 2013.
[2] P. Perucca and F. G. Gilliam. Adverse effects of antiepileptic drugs. The Lancet Neurology, 11
(9):792–802, 2012.
[3] R. Toledano and A. Gil-Nagel. Adverse effects of antiepileptic drugs. Semin Neurol, 28(3):317–27,
2008.
[4] M. A. Rogawski. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy
research, 68(1):22–28, 2006.
[5] R. Sankar and G. L. Holmes. Mechanisms of action for the commonly used antiepileptic drugs:
Relevance to antiepileptic drug–associated neurobehavioral adverse effects. Journal of Child Neu-
rology, 19(1 suppl):S6–S14, 2004.
[6] M. A. Dichter and J. Pollard. Models of Seizures and Epilepsy, chapter Cell Culture Models for
Studying Epilepsy, pages 23–34. Elsevier Academic Press, 2006.
[7] M. J. Brodie, A. Covanis, A. Gil-Nagel, H. Lerche, E. Perucca, G. J. Sills, and H. S. White.
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy & Behavior, 21(4):
331–41, 2011.
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 24 — #30 i
i
i
i
i
i
2
24 | Chapter 2
[8] F. A. De Marco, E. Ghizoni, E. Kobayashi, L. M. Li, and F. Cendes. Cerebellar volume and
long-term use of phenytoin. Seizure, 12(5):312–315, 2003.
[9] H. R. Pardoe, A. T. Berg, and G. D. Jackson. Sodium valproate use is associated with reduced
parietal lobe thickness and brain volume. Neurology, 80(20):1895–1900, 2013.
[10] N. A. Puts and R. A. Edden. In vivo magnetic resonance spectroscopy of GABA: a methodological
review. Prog Nucl Magn Reson Spectrosc, 60:29–41, 2012.
[11] A. J. Ross and P. S. Sachdev. Magnetic resonance spectroscopy in cognitive research. Brain Res
Rev, 44(2-3):83–102, 2004.
[12] R. G. Wise and I. Tracey. The role of fMRI in drug discovery. J Magn Reson Imaging, 23(6):
862–76, 2006.
[13] J. L. Fisher. The effects of stiripentol on GABA(A) receptors. Epilepsia, 52 Suppl 2:76–8, 2011.
[14] P. Kwan and M. J. Brodie. Neuropsychological effects of epilepsy and antiepileptic drugs. The
Lancet, 357(9251):216–222, 2001.
[15] M. A. Rogawski and W. Loscher. The neurobiology of antiepileptic drugs. Nat Rev Neurosci, 5
(7):553–64, 2004.
[16] L. J. Stephen and M. J. Brodie. Pharmacotherapy of epilepsy. CNS drugs, 25(2):89–107, 2011.
[17] H. S. White, M. D. Smith, and K. S. Wilcox. Mechanisms of action of antiepileptic drugs. Inter-
national review of neurobiology, 81:85–110, 2007.
[18] C. Johannessen Landmark, S. I. Johannessen, and T. Tomson. Host factors affecting antiepileptic
drug delivery-pharmacokinetic variability. Adv Drug Deliv Rev, 64(10):896–910, 2012.
[19] P. Kwan, A. Arzimanoglou, A. T. Berg, M. J. Brodie, W. Allen Hauser, G. Mathern, S. L. Moshe,
E. Perucca, S. Wiebe, and J. French. Definition of drug resistant epilepsy: consensus proposal by
the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia, 51(6):1069–77,
2010.
[20] Y. Schiller and Y. Najjar. Quantifying the response to antiepileptic drugs effect of past treatment
history. Neurology, 70(1):54–65, 2008.
[21] D. Schmidt and W. Loscher. Drug resistance in epilepsy: putative neurobiologic and clinical
mechanisms. Epilepsia, 46(6):858–77, 2005.
[22] V. Govindaraju, K. Young, and A. A. Maudsley. Proton NMR chemical shifts and coupling con-
stants for brain metabolites. NMR in Biomedicine, 13(3):129–153, 2000.
[23] S. W. Provencher. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR
in Biomedicine, 14(4):260–264, 2001.
[24] M. E. Henry, T. L. Lauriat, M. Shanahan, P. F. Renshaw, and J. E. Jensen. Accuracy and stability
of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a
phantom study at 4 Tesla. J Magn Reson, 208(2):210–8, 2011.
[25] C. D. Rae. A guide to the metabolic pathways and function of metabolites observed in human
brain 1H magnetic resonance spectra. Neurochem Res, 39(1):1–36, 2014.
[26] S. G. Mueller, O. M. Weber, P. Boesiger, and H. G. Wieser. Influence of pyridoxal 5’-phosphate
alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy.
Brain research bulletin, 55(4):555–560, 2001.
[27] E. J. Novotny, F. Hyder, M. Shevell, and D. L. Rothman. GABA changes with vigabatrin in the
developing human brain. Epilepsia, 40(4):462–466, 1999.
[28] O. A. C. Petroff, F. Hyder, T. Collins, R. H. Mattson, and D. L. Rothman. Acute effects of
vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia,
40(7):958–964, 1999.
[29] O. A. C. Petroff, D. L. Rothman, K. L. Behar, and R. H. Mattson. Initial observations on effect
of vigabatrin on in vivo 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and
glutamine in human brain. Epilepsia, 36(5):457–464, 1995.
[30] O. A. C. Petroff, D. L. Rothman, K. L. Behar, T. L. Collins, and R. H. Mattson. Human brain
GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology, 47(6):1567–1571, 1996.
[31] N. P. L. G. Verhoeff, O. A. C. Petroff, F. Hyder, S. S. Zoghbi, M. Fujita, N. Rajeevan, D. L.
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 25 — #31 i
i
i
i
i
i
2
MR biomarkers of antiepileptic drug effectiveness | 25
Rothman, J. P. Seibyl, R. H. Mattson, and R. B. Innis. Effects of vigabatrin on the GABAergic
system as determined by [123I] iomazenil SPECT and GABA MRS. Epilepsia, 40(10):1433–1438,
1999.
[32] O. M. Weber, A. Verhagen, C. O. Duc, D. Meier, K. L. Leenders, and P. Boesiger. Effects of
vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance
spectroscopy and positron emission tomography. Magnetic resonance imaging, 17(3):417–425,
1999.
[33] R. Kuzniecky, H. Hetherington, S. Ho, J. Pan, R. Martin, F. Gilliam, J. Hugg, and E. Faught.
Topiramate increases cerebral GABA in healthy humans. Neurology, 51(2):627–629, 1998.
[34] R. Kuzniecky, S. Ho, J. Pan, R. Martin, F. Gilliam, E. Faught, and H. Hetherington. Modulation
of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology, 58
(3):368–372, 2002.
[35] O. A. C. Petroff, F. Hyder, R. H. Mattson, and D. L. Rothman. Topiramate increases brain GABA,
homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology, 52(3):473–473, 1999.
[36] O. A. C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Topiramate rapidly raises brain
GABA in epilepsy patients. Epilepsia, 42(4):543–548, 2001.
[37] K. Cai, R. P. Nanga, L. Lamprou, C. Schinstine, M. Elliott, H. Hariharan, R. Reddy, and C. N.
Epperson. The impact of gabapentin administration on brain GABA and glutamate concentrations:
a 7T (1)H-MRS study. Neuropsychopharmacology, 37(13):2764–71, 2012.
[38] O. A. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Effects of gabapentin on brain GABA,
homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia, 41(6):675–80, 2000.
[39] O. A. Petroff, D. L. Rothman, K. L. Behar, D. Lamoureux, and R. H. Mattson. The effect of
gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol, 39(1):95–9,
1996.
[40] N. Preuss, J. W. van der Veen, P. J. Carlson, J. Shen, and G. Hasler. Low single dose gabapentin
does not affect prefrontal and occipital gamma-aminobutyric acid concentrations. Eur Neuropsy-
chopharmacol, 23(12):1708–13, 2013.
[41] O. A. C. Petroff, D. L. Rothman, K. L. Behar, and R. H. Mattson. Human brain GABA levels
rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology,
46(5):1459–1459, 1996.
[42] O. A. C. Petroff, K. L. Behar, R. H. Mattson, and D. L. Rothman. Human brain γ-aminobutyric
acid levels and seizure control following initiation of vigabatrin therapy. Journal of neurochem-
istry, 67(6):2399–2404, 1996.
[43] S. G. Mueller, O. M. Weber, C. O. Duc, B. Weber, D. Meier, W. Russ, P. Boesiger, and H. G.
Wieser. Effects of vigabatrin on brain GABA+/Cr signals in patients with epilepsy monitored by
1H-NMR-spectroscopy: Responder characteristics. Epilepsia, 42(1):29–40, 2001.
[44] S. G. Mueller, O. M. Weber, C. O. Duc, D. Meier, W. Russ, P. Boesiger, and H. G. Wieser. Effects
of vigabatrin on brain GABA+/Cr signals in focus distant and focus near brain regions monitored
by 1H-NMR spectroscopy. European Journal of Neurology, 10(1):45–52, 2003.
[45] J. F. Myers, C. J. Evans, N. J. Kalk, R. A. Edden, and A. R. Lingford-Hughes. Measurement of
GABA using J-difference edited 1H-MRS following modulation of synaptic GABA concentration
with tiagabine. Synapse, 68(8):355–62, 2014.
[46] M. T. Doelken, T. Hammen, W. Bogner, A. Mennecke, A. Stadlbauer, U. Boettcher, A. Doerfler,
and H. Stefan. Alterations of intracerebral gamma-aminobutyric acid (GABA) levels by titration
with levetiracetam in patients with focal epilepsies. Epilepsia, 51(8):1477–82, 2010.
[47] R. Kuzniecky, J. Pan, A. Burns, O. Devinsky, and H. Hetherington. Levetiracetam has no acute
effects on brain γ-aminobutyric acid levels. Epilepsy & Behavior, 12(2):242–244, 2008.
[48] O. A. C. Petroff. Book review: GABA and glutamate in the human brain. The Neuroscientist, 8
(6):562–573, 2002.
[49] O. A. C. Petroff, R. H. Mattson, K. L. Behar, F. Hyder, and D. L. Rothman. Vigabatrin increases
human brain homocarnosine and improves seizure control. Annals of neurology, 44(6):948–952,
1998.
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 26 — #32 i
i
i
i
i
i
2
26 | Chapter 2
[50] O. A. C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Brain homocarnosine and seizure
control of patients taking gabapentin or topiramate. Epilepsia, 47(3):495–498, 2006.
[51] O. A. C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Homocarnosine and seizure control
in juvenile myoclonic epilepsy and complex partial seizures. Neurology, 56(6):709–715, 2001.
[52] P. Brambilla, J. A. Stanley, M. Nicoletti, K. Harenski, K. F. Wells, A. G. Mallinger, M. S. Ke-
shavan, and J. C. Soares. 1H MRS brain measures and acute lorazepam administration in healthy
human subjects. Neuropsychopharmacology, 26:546–551, 2002.
[53] M. E. Henry, J. E. Jensen, S. C. Licata, C. Ravichandran, M. L. Butman, M. Shanahan, T. L.
Lauriat, and P. F. Renshaw. The acute and late CNS glutamine response to benzodiazepine chal-
lenge: A pilot pharmacokinetic study using proton magnetic resonance spectroscopy. Psychiatry
Research: Neuroimaging, 184(3):171–176, 2010.
[54] R. J. Simister, M. A. McLean, G. J. Barker, and J. S. Duncan. The effect of sodium valproate on
proton MRS visible neurochemical concentrations. Epilepsy Res, 74(2-3):215–9, 2007.
[55] C. M. Moore, M. Wardrop, B. Frederick B. de, and P. F. Renshaw. Topiramate raises anterior
cingulate cortex glutamine levels in healthy men; a 4.0T magnetic resonance spectroscopy study.
Psychopharmacology (Berl), 188(2):236–43, 2006.
[56] B. A. Campos, C. L. Yasuda, G. Castellano, E. Bilevicius, L. M. Li, and F. Cendes. Proton MRS
may predict AED response in patients with TLE. Epilepsia, 51(5):783–8, 2010.
[57] R. J. Simister, M. A. McLean, G. J. Barker, and J. S. Duncan. Proton MRS reveals frontal lobe
metabolite abnormalities in idiopathic generalized epilepsy. Neurology, 61(7):897–902, 2003.
[58] M. P. van den Heuvel and H. E. Hulshoff Pol. Exploring the brain network: a review on resting-
state fMRI functional connectivity. Eur Neuropsychopharmacol, 20(8):519–34, 2010.
[59] R. L. Aupperle, D. Tankersley, L. N. Ravindran, T. Flagan, N. R. Stein, M. B. Stein, and M. P.
Paulus. Pregabalin effects on neural response to emotional faces. Front Hum Neurosci, 6:42, 2012.
[60] C. M. Del-Ben, C. A. Ferreira, T. A. Sanchez, W. C. Alves-Neto, V. G. Guapo, D. B. de Araujo,
and F. G. Graeff. Effects of diazepam on BOLD activation during the processing of aversive faces.
J Psychopharmacol, 26(4):443–51, 2012.
[61] G. D. Iannetti, L. Zambreanu, R. G. Wise, T. J. Buchanan, J. P. Huggins, T. S. Smart, W. Vennart,
and I. Tracey. Pharmacological modulation of pain-related brain activity during normal and central
sensitization states in humans. Proceedings of the National Academy of Sciences of the United
States of America, 102(50):18195–18200, 2005.
[62] X. Li, C. C. Teneback, Z. Nahas, F. A. Kozel, C. Large, J. Cohn, D. E. Bohning, and M. S. George.
Interleaved transcranial magnetic stimulation/functional MRI confirms that lamotrigine inhibits
cortical excitability in healthy young men. Neuropsychopharmacology, 29(7):1395–407, 2004.
[63] Z. Munoz-Torres, J. L. Armony, D. Trejo-Martinez, R. Conde, and M. Corsi-Cabrera. Behavioural
and neural effects of diazepam on a rule-guided response selection task. Neurosci Res, 70(3):260–8,
2011.
[64] M. P. Paulus, J. S. Feinstein, G. Castillo, A. N. Simmons, and M. B. Stein. Dose-dependent
decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing.
Archives of General Psychiatry, 62(3):282–288, 2005.
[65] M. Ragnehed, I. H˚akansson, M. Nilsson, P. Lundberg, B. So¨derfeldt, and M. Engstro¨m. Influence of
diazepam on clinically designed fMRI. The Journal of neuropsychiatry and clinical neurosciences,
19(2):164–172, 2007.
[66] H. Jokeit, M. Okujava, and F. G. Woermann. Carbamazepine reduces memory induced activation
of mesial temporal lobe structures: a pharmacological fMRI-study. BMC Neurol, 1:6, 2001.
[67] X. Li, C. H. Large, R. Ricci, J. J. Taylor, Z. Nahas, D. E. Bohning, P. Morgan, and M. S. George.
Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI)
and dynamic causal modeling to understand the discrete circuit specific changes of medications:
lamotrigine and valproic acid changes in motor or prefrontal effective connectivity. Psychiatry
Res, 194(2):141–8, 2011.
[68] X. Li, R. Ricci, C. H. Large, B. Anderson, Z. Nahas, D. E. Bohning, and M. S. George. Inter-
leaved transcranial magnetic stimulation and fMRI suggests that lamotrigine and valproic acid
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 27 — #33 i
i
i
i
i
i
2
MR biomarkers of antiepileptic drug effectiveness | 27
have different effects on corticolimbic activity. Psychopharmacology (Berl), 209(3):233–44, 2010.
[69] E. C. Bell, M. C. Willson, A. H. Wilman, S. Dave, and P. H. Silverstone. Differential effects of
chronic lithium and valproate on brain activation in healthy volunteers. Hum Psychopharmacol,
20(6):415–24, 2005.
[70] R. L. Aupperle, L. Ravindran, D. Tankersley, T. Flagan, N. R. Stein, A. N. Simmons, M. B. Stein,
and M. P. Paulus. Pregabalin influences insula and amygdala activation during anticipation of
emotional images. Neuropsychopharmacology, 36(7):1466–77, 2011.
[71] E. A. Thomas and S. Petrou. Network-specific mechanisms may explain the paradoxical effects of
carbamazepine and phenytoin. Epilepsia, 54(7):1195–202, 2013.
[72] Z. Haneef, H. S. Levin, and S. Chiang. Brain graph topology changes associated with anti-epileptic
drug use. Brain Connect, 5(5):284–91, 2015.
[73] J. F. Jansen, A. P. Aldenkamp, H. J. Marian Majoie, R. P. Reijs, M. C. de Krom, P. A. Hofman,
M. Eline Kooi, K. Nicolay, and W. H. Backes. Functional MRI reveals declined prefrontal cortex
activation in patients with epilepsy on topiramate therapy. Epilepsy Behav, 9(1):181–5, 2006.
[74] A. De Ciantis, M. Muti, C. Piccolini, M. Principi, A. Di Renzo, R. De Ciantis, D. Frondizi,
G. Iannone, P. Ottaviano, and M. Piccirilli. A functional MRI study of language disturbances
in subjects with migraine headache during treatment with topiramate. Neurol Sci, 29 Suppl 1:
S141–3, 2008.
[75] J. P. Szaflarski and J. B. Allendorfer. Topiramate and its effect on fMRI of language in patients
with right or left temporal lobe epilepsy. Epilepsy Behav, 24(1):74–80, 2012.
[76] C. L. Yasuda, M. Centeno, C. Vollmar, J. Stretton, M. Symms, F. Cendes, M. A. Mehta, P. Thomp-
son, J. S. Duncan, and M. J. Koepp. The effect of topiramate on cognitive fMRI. Epilepsy Res,
105(1-2):250–5, 2013.
[77] B. Wandschneider, J. Stretton, M. Sidhu, M. Centeno, L. R. Koza´k, M. Symms, P. J. Thompson,
J. S. Duncan, and M. J. Koepp. Levetiracetam reduces abnormal network activations in temporal
lobe epilepsy. Neurology, 83(17):1508–1512, 2014.
[78] B. P. Kay, M. W. DiFrancesco, M. D. Privitera, J. Gotman, S. K. Holland, and J. P. Szaflarski.
Reduced default mode network connectivity in treatment-resistant idiopathic generalized epilepsy.
Epilepsia, 54(3):461–70, 2013.
[79] N. W. Duncan, C. Wiebking, and G. Northoff. Associations of regional GABA and glutamate
with intrinsic and extrinsic neural activity in humans – a review of multimodal imaging studies.
Neurosci Biobehav Rev, 47C:36–52, 2014.
[80] C. J. Stagg, S. Bestmann, A. O. Constantinescu, L. M. Moreno, C. Allman, R. Mekle, M. Woolrich,
J. Near, H. Johansen-Berg, and J. C. Rothwell. Relationship between physiological measures of
excitability and levels of glutamate and GABA in the human motor cortex. J Physiol, 589(Pt 23):
5845–55, 2011.
[81] J. A. Detre, H. Rao, D. J. Wang, Y. F. Chen, and Z. Wang. Applications of arterial spin labeled
MRI in the brain. J Magn Reson Imaging, 35(5):1026–37, 2012.
[82] P. Beleza. Refractory epilepsy: a clinically oriented review. Eur Neurol, 62(2):65–71, 2009.
[83] Z. J. Wang, C. Bergqvist, J. V. Hunter, D. Jin, D. J. Wang, S. Wehrli, and R. A. Zimmerman. In
vivo measurement of brain metabolites using two-dimensional double-quantum MR spectroscopy–
exploration of GABA levels in a ketogenic diet. Magn Reson Med, 49(4):615–9, 2003.
[84] J. W. Pan, R. B. Duckrow, J. Gerrard, C. Ong, L. J. Hirsch, Jr. Resor, S. R., Y. Zhang, O. Petroff,
S. Spencer, H. P. Hetherington, and D. D. Spencer. 7T MR spectroscopic imaging in the localization
of surgical epilepsy. Epilepsia, 54(9):1668–78, 2013.
[85] D. L. Rothman, H. M. De Feyter, R. A. de Graaf, G. F. Mason, and K. L. Behar. 13C MRS studies
of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed, 24(8):943–57, 2011.
[86] E. A. van Vliet, W. M. Otte, J. A. Gorter, R. M. Dijkhuizen, and W. J. Wadman. Longitudinal
assessment of blood-brain barrier leakage during epileptogenesis in rats. a quantitative MRI study.
Neurobiol Dis, 63:74–84, 2014.
[87] M. P. van den Heuvel, C. J. Stam, R. S. Kahn, and H. E. Hulshoff Pol. Efficiency of functional
brain networks and intellectual performance. J Neurosci, 29(23):7619–24, 2009.
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 28 — #34 i
i
i
i
i
i
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 29 — #35 i
i
i
i
i
i
Chapter 3
Glutamate concentrations vary with
antiepileptic drug use and mental slowing
T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, R. H. C. Lazeron, N. A. J.
Puts, R. A. E. Edden, P. A. M. Hofman, A. J. A. de Louw, W. H. Backes,
J. F. A. Jansen, Epilepsy&Behavior 2016; 64: 200–205,
DOI: 10.1007/s10439-014-1198-y
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 30 — #36 i
i
i
i
i
i
3
30 | Chapter 3
Abstract
Objective: Although antiepileptic drugs (AEDs) are effective in suppressing epilep-
tic seizures, they also induce (cognitive) side effects, with mental slowing as a gen-
eral effect. This study aimed to assess whether concentrations of the MR detectable
neurotransmitters glutamate and GABA are associated with mental slowing in pa-
tients with epilepsy taking AEDs.
Methods: Cross-sectional data were collected from 55 patients with localization-
related epilepsy using a variety of AEDs from three risk categories, i.e. AEDs with
low, intermediate, and high risks of developing cognitive problems. Patients under-
went 3T MR spectroscopy, including a PRESS (n=55) and MEGA-PRESS (n=43)
sequence, to estimate occipital glutamate and GABA concentrations, respectively.
The association was calculated between neurotransmitter concentrations and cen-
tral information processing speed, which was measured using the Computerized
Visual Searching Task (CVST) and compared between the different risk categories.
Results: Combining all groups, patients with lower processing speeds had lower
glutamate concentrations. Patients in the high-risk category had a lower glutamate
concentration and lower processing speed compared with patients taking low-risk
AEDs. Patients taking intermediate-risk AEDs also had a lower glutamate con-
centration compared with patients taking low-risk AEDs, but processing speed did
not differ significantly between those groups. No associations were found between
the GABA concentration and risk category or processing speed.
Conclusion: For the first time a relation is shown between glutamate concen-
tration and both mental slowing and AED use. It is suggested that the reduced
excitatory action, reflected by lowered glutamate concentrations, may have con-
tributed to the slowing of information processing in patients using AEDs with
higher risks of cognitive side effects.
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Introduction
Although antiepileptic drugs (AEDs) are effective in suppressing epileptic seizures,
they may also induce side effects. These side effects can strongly affect the qual-
ity of life of patients, with slowing of central information processing speed as the
dominant cognitive effect of most AEDs and also the first sign of cognitive adverse
effects [1, 2]. Cognitive side effects are commonly seen among the different AED
regimes, but the occurrence and severity vary between different AEDs. The newer
AEDs lamotrigine and levetiracetam are suggested to have no adverse, and maybe
even beneficial cognitive effects, while topiramate is known for its deleterious cog-
nitive effects. Other AEDs, such as valproate or carbamazepine, are associated
with milder cognitive effects [1, 3, 4].
AEDs aim to control epileptic seizures via a number of distinct mechanisms of
action, which can be subdivided in suppression of the excitatory mechanisms or en-
hancement of inhibitory mechanisms [5]. Although cognitive side effects are likely
to result from the anticonvulsant activity of the AEDs, these effects cannot be
linked to any particular mechanism of action, and other mechanisms might be in-
volved as well [6]. It has been hypothesized that especially AEDs with mechanisms
acting on the γ-aminobutyric acid (GABA) system cause cognitive side effects, but
similar side effects are also induced by AEDs with other mechanisms of action [7].
Furthermore, it is currently not possible to predict which patients will suffer from
these side effects and who will not. However, compliance to AED therapy relies on
efficacy as well as tolerance to side effects.
In vivo measurements of the main inhibitory and excitatory neurotransmitters
GABA and glutamate can be provided by proton magnetic resonance spectroscopy
(1H-MRS). In healthy individuals, higher GABA concentrations and lower gluta-
mate concentrations have been associated with better cognitive performance [8–
10]. Previous studies also showed that AED treatment can be associated with
altered neurotransmitter concentrations [11]. Although several studies have been
performed to associate GABA and glutamate concentrations with seizure con-
trol [12–14], to our knowledge the association with cognitive side effects has not
been investigated yet. The aim of this cross-sectional study was to assess whether
GABA and glutamate concentrations can be linked to cognitive functioning, in
terms of decreased processing speed, in patients with epilepsy on long-term AED
treatment.
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Methods
Patients
Patients with localization-related epilepsy, recruited from our tertiary epilepsy re-
ferral center, were included in this study. Inclusion criteria were an age between 18
and 70 years and no contraindications for MRI (metal implants, claustrophobia, or
pregnancy). This study was approved by the local Medical Ethical Committee and
written informed consent was obtained from all patients before the examination.
To obtain a variation in information processing speed, three groups of patients
using different AEDs were included. The groups were defined according to Sama-
rasekera et al. [15], based on the known risk of developing cognitive side effects:
a low-risk category (levetiracetam and lamotrigine), an intermediate-risk category
(valproate, carbamazepine, oxcarbazepine and phenytoin), and a high-risk cate-
gory (topiramate). Both patients on mono- and polytherapy were included, but
patients took maximal two different AEDs. Patients on polytherapy were classified
according to the AED in the highest risk category.
Neuropsychological investigation
Information processing speed was used as a measure for cognitive side effects, as
slowing of central information processing speed is the most common side effect of
AEDs [2]. For this, the Computerized Visual Searching Task (CVST) was used [16].
In this task, a centered grid pattern has to be compared with 24 surrounding
grid patterns. Participants have to find the grid pattern identical to the centered
pattern. The score is the average time needed to complete this task. Additionally,
as global cognitive abilities are assumed to be unaffected by AEDs [2], the Raven
Standard Progressive Matrices was performed to correct for possible variation in
cognitive abilities between the patients [17]. This is a non-verbal reasoning test, in
which participants have to identify the figure that is required to fulfill a series of
eight other figures.
Data acquisition
MR data were acquired on a 3.0T MR scanner equipped with an 8-channel head
coil (Philips Achieva, Philips Medical Systems, Best, the Netherlands). Glutamate
concentrations were measured using a PRESS sequence (TE/TR: 35/2000 ms, 128
averages, VAPOR water suppression). GABA-edited MR spectra were acquired
using a MEGA-PRESS sequence (TE/TR 68/2000 ms, 320 averages, with editing
pulses at 1.9 (ON) and 7.46 ppm (OFF) interleaved in 40 blocks, MOIST water
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Figure 3.1. Example of the voxel placement (A), a PRESS spectrum with the LCModel fit (in red),
which fits a linear combination of metabolite spectra (B), and a MEGA-PRESS spectrum with the
GANNET fit (in red), which only fits the GABA+ peak (GABA + co-edited macromolecules) (C).
Individual glutamate or GABA fits are displayed in the figures as well.
suppression). Both spectra were acquired from the same 3x3x3 cm3 voxel located
around the parieto-occipital sulcus (Figure 3.1). This location has an optimal
signal-to-noise ratio and is commonly selected in MRS studies [18]. To estimate
the water signal, separate scans without water suppression were made directly after
the PRESS and MEGA-PRESS scans (with TE/TR 35/2000 ms and 128 averages
or TE/TR 68/2000 ms and 8 averages, respectively). Additionally, a T1-weighted
scan was made to determine the voxel composition (voxel size 1x1x1 mm3, flip
angle 8◦, 3D fast spoiled gradient echo sequence, TE/TI/TR 4.8/1022/8.3 ms, 180
slices).
Data analysis
PRESS spectra were analyzed using LCModel (version 6.3-1L). LCModel fits the
spectrum with a linear combination of individual metabolite spectra [19]. A stan-
dard basis set with sixteen different simulated metabolite spectra was used in
this analysis and spectra were analyzed within the resonance frequency range
from 0.2 to 4.0 ppm. In addition to glutamate, tNAA (N-acetyl aspartate + N-
acetylaspartylglutamate), tCho (phosphorylcholine + glycerophosphorylcholine),
and tCr (creatine + phosphocreatine) concentration estimates were collected for
further analyses.
Gannet (version 2.0) was used for the preprocessing and quantification of the
GABA+ concentration (i.e. GABA and co-edited macromolecules) [20]. The
GABA peak is fitted to a Gaussian model curve. Gannet is designed for GABA+
quantification but also enables Glx quantification from MEGA-PRESS spectra [21].
Gannet has the advantage that it also includes frequency and phase corrections [22,
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23]. MEGA-PRESS scans are more vulnerable for field drifts and movement ar-
tifacts than typical PRESS scans because of the addition of an editing pulse and
subtraction of ON and OFF scans to obtain difference spectra, potentially leading
to subtraction artifacts. Frequency correction can reduce quantification errors [22].
All spectra were visually inspected on subtraction artifacts and adequate noise
levels.
Repeatability of these methods was tested in five healthy volunteers (age 29±4
year, four male), who underwent two PRESS and MEGA-PRESS scans immedi-
ately after each other. The results showed a coefficient of variation of 2.9%, 5.2%
and 8.1% for glutamate (using PRESS/LCModel), Glx (using MEGA-PRESS/
Gannet) and GABA+, respectively. Because of the better coefficient of variation
of glutamate estimations with PRESS than Glx estimations with MEGA-PRESS,
and because of a moderate concordance between these measurements in the in-
cluded patients (Pearson correlation coefficient=0.31, p=0.046), only glutamate
measurements with PRESS were considered in this study.
All concentrations are reported relative to the unsuppressed water signal from
the same volume. FMRIB’s Automated Segmentation Tool (FAST), part of FSL
(version 5.0.1), was applied to determine the voxel composition in terms of gray
matter, white matter, and cerebral spinal fluid (CSF) content [24, 25]. Assuming
that the neurometabolites are only present in the gray and white matter, the con-
centrations relative to the water signal were corrected for the CSF content of the
voxel. Therefore, the neurometabolite concentrations were divided by the sum of
the gray and white matter fractions.
Statistical analysis
Associations between the neurometabolite concentrations (i.e. glutamate, GABA+,
tNAA, tCho, and tCr) and CVST were tested with linear regression analysis, with
CVST as dependent variable and the concentrations as independent variables.
Separate analyses were performed for each neurometabolite. Besides the neu-
rometabolite concentration, age and the percentage correct answers in the Raven
test (as a measure for intelligence) were added to these analyses as independent
variables, as the information processing speed usually correlates with age and
cognitive abilities.
To test whether the neurometabolite concentrations varied with risk degree an
ANCOVA (analysis of covariance) test was applied, with the neurometabolite con-
centrations as outcome variable and the risk categories as fixed factors. Covariates
in the analyses were age, gender, and the gray matter fraction in the voxel (gray
matter fraction divided by the sum of the white and gray matter fractions). In
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case of significant group effects, post hoc tests (Students t-tests) were applied to
test for individual group differences.
To check for possible confounding effects, the analyses were repeated with drug
load (defined as the ratio of the prescribed daily dose to the defined daily dose [26]),
having symptomatic epilepsy or epilepsy severity added as additional covariate.
Epilepsy severity was defined by a composed score ranging from 0 to 7 based
on seizure type (tonic-clonic:1, other:0), previous occurrence of status epilepticus
(yes:1, no:0), seizure-related injury (yes:1, no:0), and seizure frequency (seizure
free:0, yearly:1, monthly:2, weekly:3, daily:4). In all analyses, p-values<0.05 were
considered significant.
Results
Patient characteristics
Fifty-eight patients were included in this study. Three of these patients did not
finish the MRI examination because of claustrophobia, resulting in suitable data
of 55 patients for further analysis. Seventeen of the 55 patients had symptomatic
epilepsy. MRI lesions included cerebral atrophy (6), cortical dysplasias (5), infarc-
tions (3), malformations (1), tumors (1), and cysts (1). The remaining 38 patients
had non-symptomatic epilepsy.
The low- and intermediate-risk groups differed significantly in age and drug
load (Table 3.1). Also the number of patients taking polytherapy was significantly
higher in the intermediate- and high-risk categories than in the low-risk category.
Patients in the different risk categories did not differ significantly in educational
level, seizure frequency, epilepsy severity score, or years since epilepsy onset.
The CVST reaction time ranged from 7.3 to 30.8 s (mean±sd in a healthy
adult population: 10.3±4.1 s [28]). Both the patients taking intermediate-risk and
high-risk AEDs had a significantly lower processing speed compared with patients
taking low-risk AEDs (p=0.003 and p=0.042, respectively, Table 3.1). When age,
gender, and the percentage correct answers in the Raven test were added as co-
variates to this analysis (ANCOVA), there was a significant effect of risk category
(p=0.009). Post hoc tests revealed a significantly longer CVST reaction time in
the intermediate- (p=0.035, adjusted mean difference: 3.5 s), and in the high-risk
categories (p=0.004, adjusted mean difference: 7.8 s), compared with patients tak-
ing low-risk AEDs. The CVST reaction time did not differ significantly between
the intermediate- and high-risk groups. All participants had a Raven score above
the 5th percentile of a healthy, age-matched adult population, and the Raven score
was not significantly different between the groups.
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Table 3.1. Patient characteristics for the three risk categoriesa. Results are displayed for the partici-
pants included in the PRESS analysis.
Low-risk Intermediate-risk High-risk
(n=16) (n=34) (n=5)
General
Male/female 5/11 (31/69%) 16/18 (47/53%) 0/5
Age (years)b 39.5±13.4 50.7±12.5* 42.4±15.8
Educational levelc 5 (range 2-6) 5 (range 2-7) 5 (range 4-6)
Epilepsy-related
Symptomatic/non-
symptomatic epilepsy
2/14 (13/88%) 15/19 (44/56%) 0/5
Seizure frequency
Weekly 0 1 (3%) 0
Monthly 4 (25%) 3 (9%) 0
Yearly 2 (13%) 6 (18%) 2 (40%)
Seizure free 10 (63%) 24 (71%) 3 (60%)
Years since epilepsy onsetb 22.7±11.7 30.4±13.4 26.8±23.3
Epilepsy severite scoreb 1.4±0.8 1.2±1.0 1.0±0.7
AED-related
Mono-/polytherapy 16/0 8/26 (24/77%)* 3/2 (60/40%)†
Medication type
CBZ 0 17 (50%) 1 (20%)
LEV 7 (44%) 6 (18%) 0
LTG 9 (56%) 10 (29%) 1 (20%)
OXC 0 4 (12%) 0
PHT 0 16 (47%) 0
TPM 0 0 5 (100%)
VPA 0 7 (21%) 1 (20%)
Drug loadb,d 1.3±0.6 1.8±0.7* 1.2±1.0
Neuropsychological results
CVST reaction timeb 11.5±2.9 15.7±6.4* 20.2±6.7†
Raven (% correct answers)b 71.7±10.3% 73.2±10.1% 71.7±3.1%
Differences between the risk groups were tested using a Fisher’s exact test (gender, symptomatic
epilepsy, mono/polytherapy), a Mann-Whitney test (educational level, seizure frequency, epilepsy
severity score), or a student’s t-test (all remaining variables). *indicates significant differences be-
tween the low- and intermediate-risk category (p<0.05); †indicates differences between the low- and
high-risk categories (p<0.05).
aLow-risk: lamotrigine (LTG), levetiracetam (LEV); Intermediate-risk: valproate (VPA), carba-
mazepine (CBZ), oxcarbazepine (OXC) and phenytoin (PHT); High-risk: topiramate (TPM)
bmean ± standard deviation
cMedian (range). Scores are according to Verhage [27], range 1 (did not finish primary school) to 7
(Master’s degree)
dThe drug load is defined as the ratio of the prescribed daily dose to the defined daily dose [28]
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Spectroscopy results
The quality of the PRESS spectra was adequate in all patients. Visual inspection
did not reveal spectra of insufficient quality, all spectra had a signal-to-noise ratio
above 20, and the Crame˙ r-Rao lower bounds (CRLB) of glutamate were below
10%. Forty-three MEGA-PRESS spectra were included in the statistical analysis
(15 from the low-risk group, 26 from the intermediate-risk group, and 2 from the
high-risk group). In four patients, no MEGA-PRESS data were available because
of acquisition problems, and another eight MEGA-PRESS scans were excluded
because of insufficient quality of the spectrum. The error of the GABA fit was
below 15% in the remaining spectra, while the mean absolute drift of the water
peak between two subsequent blocks was 0.009±0.004 ppm.
Across all participants, the glutamate and GABA concentrations were 9.3±0.8
i.u. (institutional units) and 1.7±0.4 i.u., respectively (mean±sd). tNAA, tCr, and
tCho concentrations were 9.0±0.5 i.u., 6.8±0.6 i.u., and 1.2±0.2 i.u., respectively.
The CVST reaction time was significantly associated with glutamate concentra-
tion (β=-3.1, p=0.001, with correction for age and global intelligence), indicating
that patients with a lower processing speed had a lower glutamate concentration
(Figure 3.2). The CVST reaction time was not significantly associated with the
GABA (p=0.45), tNAA (p=0.99), tCr (p=0.82), or tCho (p=0.13) concentrations.
The glutamate and GABA concentrations are illustrated for the different groups
in Figure 3.3. A significant effect of cognitive risk category on the glutamate con-
centration was observed (p=0.028, ANCOVA, with age, gender, and gray matter
fraction as covariates). Post hoc tests showed a significantly lower glutamate con-
centration in the intermediate-risk category than in the low-risk category (p=0.021,
adjusted mean difference 0.49) and in the high- compared with the low-risk category
(p=0.032, adjusted mean difference 0.72). The intermediate- and high-risk cate-
gories did not differ significantly in the glutamate concentrations (p=0.47). Risk
category did not have a significant effect on the GABA (p=0.83), tNAA (p=0.47),
tCho (p=0.085), or tCr (p=0.17) concentration.
The additional analyses, with epilepsy severity score, drug load, or having symp-
tomatic epilepsy added as covariates, showed comparable results as the analyses
without these additional covariates (<10% change in effect size). Furthermore,
epilepsy severity, drug load, or having symptomatic epilepsy was not a significant
covariate in any of the analyses.
i
i
“Thesis-vanVeenendaal” — 2017/5/23 — 16:10 — page 38 — #44 i
i
i
i
i
i
3
38 | Chapter 3
7 8 9 10 11 
10 
20 
30 
C
V
ST
 r
ea
ct
io
n
 t
im
e 
(s
) 
glutamate concentration (i.u.) 
low risk 
intermediate risk 
high risk 
Figure 3.2. Association of the glutamate concentration and CVST reaction time. Patients with lower
glutamate concentrations, had a longer CVST reaction time, i.e. a lower processing speed, than
patients with higher glutamate concentrations. The depicted line represents the uncorrected linear
regression estimate to guide the eye. This association remained significant after correction for age and
global intelligence (β=-3.1, p=0.001). It can be noticed that patients taking low-risk AEDs (open
circles), had high glutamate concentrations and low-CVST reaction times, while lower glutamate
concentrations and higher CVST reaction times were only measured in patients taking intermediate-
(gray circles) or high-risk (black circles) AEDs. CVST: computerized visual searching task
Discussion
This study assessed associations between neurotransmitter concentrations, AED
treatment, and cognitive functioning in patients with epilepsy. Lower glutamate
concentrations were associated with a lower processing speed, the most common
type of drug-induced cognitive impairment. Furthermore, patients taking AEDs
from higher-risk categories had lower glutamate concentrations than patients taking
AEDs from lower-risk categories. No significant associations were found between
the GABA+ concentration and risk category or processing speed.
Glutamate concentrations and cognitive slowing
To our knowledge, this is the first study showing associations between neurotrans-
mitter concentrations and drug-induced cognitive side effects (i.e. mental slowing)
in patients with epilepsy. Studies in other diseases did also show associations be-
tween the glutamate concentration and cognitive functioning, but the variety of the
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Figure 3.3. Glutamate (A) and GABA (B) concentrations for the three risk groups. Concentrations
are relative to the water concentration, corrected for the cerebral spinal fluid content of the voxel,
and displayed in institutional units. Low-risk category: lamotrigine or levetiracetam; Intermediate-
risk category: carbamazepine, oxcarbazepine, phenytoin or valproate; High-risk category: topiramate.
Standard deviations are displayed with error bars. *indicate significant differences (p<0.05), when
adjusted for age, gender, and gray matter fraction.
applied cognitive tests is large, and both positive and negative associations have
been found [29]. Different explanations are proposed for these associations. For in-
stance, it is hypothesized that neurotoxic effects of high glutamate concentrations
affect cognitive functioning [30], that a higher GABA/glutamate concentration
improves decision-making [8], or that glutamate concentration acts as a marker
for neuronal integrity [31]. Precise associations between glutamate and cognitive
function and the underlying mechanisms may depend on the specific disease and
cognitive functions being studied.
The glutamate concentration measured by MRS is a combination of gluta-
mate functioning as neurotransmitter and glutamate stored in synaptic vesicles
and metabolic pools. Although the precise mechanisms are unknown, the gluta-
mate concentration appears to be roughly linearly related to excitatory activity,
possibly because of its involvement in the glucose metabolism in the brain [32, 33].
As AEDs generally tend to suppress (abnormal) brain activity [5], it seems likely
that the lower glutamate concentrations in this study reflect more suppressed brain
activity, which may be associated with a slowing of information processing at the
downside of this effect.
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AED use and glutamate concentrations
Although differences in glutamate concentrations were observed between the dif-
ferent risk categories, none of the known mechanisms of action of AEDs are likely
to affect the glutamate concentration directly [5]. However, it is possible that
modulation of the sodium channels, seen in PHT, CBZ, OXC, TPM, and VPA,
which blocks high-frequency repetitive action potentials, indirectly decreases the
glutamate release. Three previous longitudinal studies showed no changes in the
Glx concentration (glutamate and its precursor glutamine combined) after VPA
use, or glutamate concentrations after TPM or LEV use [34–36], AEDs which were
also used in the current study. Taken together, the current study does not provide
evidence that AEDs from different risk categories alter glutamate concentrations
directly, but the results do suggest a link between glutamate concentration and
mental slowing due to AED use.
GABA
In this study, no associations were found between the GABA concentration and
information processing speed or cognitive risk category, in contrast to the hypoth-
esized involvement of GABAergic mechanisms in cognitive side effects of AEDs [7,
37]. Existing associations might have been undetected in this study because of the
small group size. Because of exclusion of MEGA-PRESS spectra, this group size
was smaller compared with the other results (n=43 versus n=55). Also confound-
ing effects of the different AEDs might have had different effects on the GABA
concentration. For instance, both TPM and LTG are suggested to increase the
GABA concentration, but a higher increase was reported with TPM use than with
LTG use [38]. Using the current clinical study design, it is not feasible to assess
distinct effects of the different AEDs, because of the many different combinations
of AEDs which were being used by the included patients. However, it cannot be
excluded that for individual AEDs, also GABA concentrations are associated with
cognitive functioning.
Other neurometabolites
tNaa, tCho, and tCr concentrations were not significantly associated with CVST
reaction time nor risk group in this study, while previous studies did show associ-
ations with for example NAA and information processing speed [39] or executive
functioning [40] in healthy elderly populations. Age-specific mechanisms may un-
derlie these associations, which cannot be generalized to other study populations.
For instance, NAA is considered a marker for neuronal integrity and is often asso-
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ciated with cognitive functioning. However, cognitive side effects of AED use are
reversible and, therefore, not likely to be accompanied by neuronal cell damage as
might be the case in aging. Previous studies have not reported associations with
tNAA, tCho, or tCr and AED use [11].
Study considerations
This study was performed in patients with epilepsy on long-term AED treatment,
which is most relevant for clinical practice. However, inherent to these studies is the
heterogeneity of the study population and the different combinations of AEDs that
were taken. An important possible confounder in this study is whether patients
were on mono- or polytherapy, which largely coincides with taking AEDs from
the low- or intermediate-risk category. Importantly, polytherapy itself is already
associated with a higher risk of cognitive side effects [41]. It can furthermore not be
excluded that both glutamate concentrations and processing speed were affected by
epilepsy characteristics or underlying causes rather than AED use. Future studies
are needed to distinguish these factors, and to clarify the precise, causal relationship
between neurotransmitter concentrations, AED use, and cognitive side effects.
Because of its negative cognitive side effects, topiramate is not commonly pre-
scribed in our epilepsy center. This resulted in a limited number of patients taking
high-risk AEDs in this study, but the results of this group are in line with the results
from the intermediate-risk category. The lack of significant differences between the
intermediate- and high-risk categories might therefore be due to the small group
size of the high-risk category.
The MRS measurements used in this study showed good repeatability. How-
ever , the low-concordance between glutamate estimations from PRESS and Glx
from MEGA-PRESS is striking. A possible explanation is the presence of macro-
molecules in one of these spectra, but future studies are prompted to investigate
this topic. A final consideration regarding MRS measurements is the voxel loca-
tion. As in many previous studies, the occipital lobe was chosen because it gives
the best signal-to-noise ratio [18, 22]. However, regions important for cognitive pro-
cesses include the prefrontal cortex and subcortical structures, and not the occipital
lobe [42]. Currently, it remains to be determined whether relevant spatial varia-
tions exist in the neurotransmitter concentrations in relation to adverse cognitive
effects.
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Future perspectives
Currently, it is not possible to predict which patients will or will not suffer from
these side effects, though this would aid clinical decision making. The results of
this study show the potential of glutamate measurements as a candidate biomarker.
In order to predict these side effects, it is necessary to first longitudinally assess
changes in neurotransmitter concentration, to see whether the differences in gluta-
mate levels possibly precede the cognitive problems or coincide with the cognitive
problems.
Conclusion
For the first time a relation is shown between lowered glutamate concentrations
and both AED use and mental slowing in patients with epilepsy. This observation
hints at a possible contribution to a neurobiological mechanism of mental slowing
due to AED use. More knowledge about this relation might help to explain why
some patients with epilepsy experience cognitive side effects while the cognitive
function of other patients is not affected by AEDs. Future studies with MRS and
AEDs are warranted to further elucidate more details of underlying mechanisms.
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Abstract
Objective: To increase our insight in the neuronal mechanisms underlying cognitive
side effects of antiepileptic drug (AED) treatment.
Methods: The relation between functional MR-acquired brain network mea-
sures, AED use, and cognitive function was investigated. Three groups of pa-
tients with epilepsy with a different risk profile for developing cognitive side ef-
fects were included: a ‘low-risk’ category (lamotrigine or levetiracetam, n=16),
an ‘intermediate-risk’ category (carbamazepine, oxcarbazepine, phenytoin, or val-
proate, n=34) and a ‘high-risk’ category (topiramate, n=5). Brain connectivity was
assessed using resting state functional MRI and graph theoretical network analysis.
The Computerized Visual Searching Task was used to measure central information
processing speed, a common cognitive side effect of AED treatment.
Results: Central information processing speed was lower in patients taking
AEDs from the intermediate- and high-risk categories, compared with patients from
the low-risk category. The effect of risk category on global efficiency was significant
(p<0.05, ANCOVA), with a significantly higher global efficiency for patient from
the low-risk category compared with the high-risk category (p<0.05, post hoc test).
Risk category had no significant effect on the clustering coefficient (ANCOVA,
p>0.2). Also no significant associations between information processing speed and
global efficiency or the clustering coefficient (linear regression analysis, p>0.15)
were observed.
Conclusion: Only the four patients taking topiramate show aberrant network
measures, suggesting that alterations in functional brain network organization may
be only subtle and measureable in patients with more severe cognitive side effects.
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Introduction
Epilepsy is generally treated with antiepileptic drugs (AEDs). A persistent problem
in AED treatment is the occurrence of adverse events among which cognitive side
effects are commonly seen [1, 2]. The cognitive side effects account for a high
percentage of the disease burden [3] and lead to early drug discontinuation [4].
The prevalence and severity of the cognitive side effects varies among different
AEDs. Several AEDs, such as topiramate, are associated with cognitive problems
such as language deficit (anomia), while other AEDs such as lamotrigine seem to
induce less cognitive side effects or even have activating effects [5]. Despite specific
differences, a decreased central information processing speed is commonly observed
among the different AEDs to some extent [2].
AEDs control epileptic seizures via several distinct mechanisms, such as en-
hancement of GABAergic inhibition, reduction of glutamatergic neurotransmission,
or modulation of the voltage-gated ion channels [6]. Changes in brain metabolic
processes also affect healthy brain activity, and are likely to be responsible for
cognitive side effects [1]. Functional magnetic resonance imaging (fMRI) enables
assessment of this brain activity, and can be employed to measure combined ef-
fects of different mechanism of action of AEDs [7]. Several fMRI studies have
shown altered brain activity patterns in healthy participants [8] or patients with
epilepsy [9, 10] treated with AEDs. For instance, altered brain activity patterns
appeared to be associated with language impairments when taking topiramate [11–
13].
Cognitive functions are mediated by the concerted action of multiple and dis-
tributed brain regions. These brain regions show correlations of their fMRI time
signals, which is commonly interpreted as functional connectivity. Collectively,
these functional connections form a brain network, which can be analyzed and
characterized using graph theoretical analysis. Brain networks appear to be effi-
cient networks, characterized by a high functional segregation and integration, i.e.
different brain regions form densely interconnected groups, enabling specialized
information processing, and also rapid communication between distributed brain
regions. Several graph measures are available to quantify these characteristics [14].
Cognitive performance has been associated with the efficiency of functional
brain networks [15, 16], while impaired functional brain networks have been associ-
ated with cognitive decline in epilepsy [17, 18]. Furthermore, associations between
drug load, cognition and graph measures were shown in one of these studies, al-
though this was not the main focus of the current study [17]. Another study
associated the use of carbamazepine with altered graph measures when compared
with other AEDs, but did not investigate the relation with cognitive effects [19]. In
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the current study, we aim to test whether chronic use of AEDs, associated with a
high risk for cognitive side effects, affects functional resting-state network measures
differently than long-term use of AEDs associated with milder cognitive side effects.
Furthermore, we will test whether functional resting-state network measures are
associated with impaired cognitive functioning.
Methods
Patients
Three groups of patients with epilepsy were compared in this observational, cross-
sectional study [20]. These groups were subdivided based on the AEDs that were
being used, in accordance to Samarasekera et al. [21]. The first group, the low-
risk category, consisted of patients using lamotrigine or levetiracetam. Patients
taking carbamazepine, oxcarbazepine, phenytoin, or valproate were included in the
intermediate-risk category, while the high-risk category comprised patients taking
topiramate. Patients on polytherapy took at most two different AEDs and were
categorized according to their AED associated with the greatest cognitive risk. By
including patients with AEDs from the three risk groups, a range in slowing of
information processing speed is set out for.
All patients were clinically diagnosed with localization-related epilepsy and aged
between 18 and 70 years. The patients were recruited from our tertiary epilepsy
referral center. Participants not eligible for MRI, because of metal implants, claus-
trophobia, or pregnancy, were excluded from this study. Furthermore, patients did
not experience seizures at least 12 hours prior to MRI. This study was approved by
the local Medical Ethical Committee and all participants provided written informed
consent.
Neuropsychological investigation
Cognitive functioning was assessed by two neuropsychological tasks. The Com-
puterized Visual Searching Task (CVST) was used to measure visual (complex)
information processing speed [22]. Slowing of this central information processing
speed is a common side effect of AEDs [2], and therefore the CVST is considered
to be sensitive for treatment effects [23]. With the CVST, a centered grid is shown
surrounded by 24 other grid patterns. Participants have to find the (only) grid
identical to the centered one as fast as possible.
The Raven Standard Progressive Matrices was administered to assess global
cognitive performance. This is a non-verbal reasoning test which gives an indication
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of fluid intelligence [24]. Previous studies suggested that intelligence stays relatively
unaffected by AEDs [25].
Epilepsy severity
As several epilepsy related characteristics might affect functional brain net-
works [26], a score was composed to account for these effects. This epilepsy severity
score was assessed in all patients and compared between the different risk cate-
gories. Epilepsy severity was characterized using a summarized score between zero
and seven, composed by the sum of subscores for seizure type (tonic-clonic: 1,
other: 0), previous occurrence of status epilepticus (yes: 1, no: 0), seizure-related
injury (yes: 1, no: 0) and seizure frequency (seizure free: 0, yearly: 1, monthly: 2,
weekly: 3, daily: 4).
MRI data acquisition
MRI data were acquired on a 3.0T MRI scanner equipped with an 8-channel head
coil (Philips Achieva, Philips Medical Systems, Best, the Netherlands). The scan-
ning protocol included resting-state functional MRI and a T1-weighted scan. Func-
tional MRI data were acquired using whole-brain single-shot multi-slice echo pla-
nar imaging (EPI) sequence sensitive to the blood-oxygen-level-dependent (BOLD)
effect (195 volumes, 32 slices, in-plane resolution 2x2 mm2, 4 mm thick slices, rep-
etition time 2000 ms, echo time 35 ms, flip angle: 90◦, acquisition time: 7 min). A
3D T1-weighted scan was acquired for anatomic reference (voxel size 1x1x1 mm3,
repetition time 8.3 ms, echo time 4.8 ms, inversion time 1022 ms, 180 slices, flip
angle 8◦, acquisition time 6 min).
Data preprocessing
Preprocessing of the functional images was performed using SPM8 (Wellcome De-
partment of Cognitive Neurology, London, UK). The functional images were cor-
rected for differences in slice timing and head movement, coregistered to the T1
image and spatially (FWHM 6 mm) and temporally filtered (band pass 0.01–0.1
Hz). The BOLD signal originating from the white matter and ventricles, which
is assumed to reflect physiological noise [27], and the six translation and rotation
parameters obtained from the motion correction were deregressed from the BOLD
signal.
The T1-weighted scan was parcellated into 82 cortical and subcortical brain
regions using FreeSurfer v5.1.0 (The General Hospital Corporation, Boston MA,
USA). Subsequently, a connectivity matrix was created by calculating the Pear-
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son’s correlation coefficient between the average (deregressed) BOLD time signal
of each combination of two regions. Negative correlations were set to zero. The
correlation values were thresholded, based on the average connectivity matrix, to
obtain connectivity matrices with only the strongest connections. The number of
included connections was varied, with sparsity levels ranging from 0 to 0.9 (0 is
fully connected, whereas 1 indicates no connections).
Data analysis
The Brain Connectivity Toolbox [14] was employed to compute graph measures
for each individual connectivity matrix. The clustering coefficient and the charac-
teristic path length are commonly used to characterize the functional segregation
and integration, respectively. The clustering coefficient quantifies the fraction of
a node’s neighbor that are also connected to each other. The characteristic path
length is defined as the average shortest distance (the inverse correlation coeffi-
cient) between all pairs of nodes. As, in sparse networks, a single weak connection
can result in a large, or even infinite average path lengths, global efficiency was
computed instead of characteristic path length, which avoids this effect by using
inverse path lengths [28].
One hundred null models of the connectivity matrices were computed by ran-
domizing the connections of the original matrices, while preserving the degree and
weight distribution [29]. The graph measures were divided by the mean global
efficiency and clustering coefficient of these null models, providing a normalized
global efficiency (Eg) and clustering coefficient (γ).
Statistical analysis
To test whether the clustering coefficient and global efficiency differed between
the risk categories, an analysis of covariance (ANCOVA) was applied with the
graph measures as outcome, cognitive risk category as fixed factor and age as
covariate. Associations with cognition were assessed with linear regression analysis,
with CVST time as outcome, and Eg or γ, age, and the percentage corrects answers
in the Raven test as independent variables. To assess whether these results were
affected by confounders, these analyses were repeated with gender, epilepsy severity
score, or drug load (ratio of prescribed daily dose to defined daily dose [30]) added
to the regression analyses as additional covariates. All statistical analyses were
performed in MATLAB (version R2012b). P-values lower than 0.05 were considered
significant.
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Results
Patient characteristics
In total, 58 patients were included in this study. Three of these patients did not
finish the procedures due to claustrophobia, resulting in 16 patients taking AEDs
from the low-risk category, 34 taking AEDs from the intermediate-risk category,
and 5 taking high-risk AEDs. The age and drug load were significantly higher in
the intermediate-risk category than in the low-risk category (Table 4.1). Also the
number of patients on polytherapy was significantly higher in the intermediate-
risk category compared with the low-risk category, while the high- and low-risk
categories significantly differed in number of patients on polytherapy. The risk cat-
egories did not differ in gender distribution, educational level, or epilepsy severity.
Neuropsychological assessment
The results of the CVST and the Raven task are summarized in Table 4.2. The
CVST reaction time was slower than the normal range (range: 7.3 to 30.8 s, while
the mean±sd was 10.3±4.1 s in normal population [32]). A significant effect of risk
category on CVST reaction time was observed, which remained significant when
controlling for age, gender, and global cognitive level (p=0.009, ANCOVA). Post
hoc tests showed significant differences in CVST between the low- and intermediate-
risk category (p=0.035, estimated adjusted mean difference 3.5 s), and between
the low- and high-risk category (p=0.004, adjusted mean difference 7.8 s). No
significant differences were found between the percentage correct answers Raven
scores of the different risk categories.
Network topology
Of the 55 included patients, seven were excluded from further analysis: one patient
was excluded because of excessive head motion (maximum head movement of 8.0
mm, while the maximum head movement was below 1.5 mm in all other patients),
one because of a deeper large lesion mass, and five patients were excluded because
of a failure to automatically parcellate the cortex, due to cortical abnormalities.
The analysis was therefore performed on 48 patients: 15 patients taking AEDs from
the low-risk category, 29 patients taking AEDs from the intermediate-risk category
and 4 patients taking the high-risk medication. The maximum head displacement
did not differ between the three risk categories. The functional networks were
fully connected and showed small-world characteristics within the sparsity range
0.32–0.66 (which was defined as γ/λ significantly larger than one, with γ the nor-
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Table 4.1. Patient characteristics for the three risk categoriesa.
Low-risk Intermediate-risk High-risk
(n=16) (n=34) (n=5)
General
Male/female 5/11 (31/69%) 16/18 (47/53%) 0/5 (0/100%)
Age (years)b 39.5±13.4 50.7±12.5* 42.4±15.8
Educational levelc 5 (range 2–6) 5 (range 2–7) 5 (range 4–6)
Epilepsy-related
Symptomatic/non-
symptomatic epilepsy
2/14 (13/88%) 15/19 (44/56%) 0/5
Seizure frequency
Weekly 0 1 (3%) 0
Monthly 4 (25%) 3 (9%) 0
Yearly 2 (13%) 6 (18%) 2 (40%)
Seizure free 10 (63%) 24 (71%) 3 (60%)
Years since epilepsy onsetb 22.7±11.7 30.4±13.4 26.8±23.3
Epilepsy severity scoreb 1.4±0.8 1.2±1.0 1.0±0.7
AED-related
Mono-/polytherapy 16/0 8/26 (24/77%)* 3/2 (60/40%)†
Medication type
CBZ 0 17 (50%) 1 (20%)
LEV 7 (44%) 6 (18%) 0
LTG 9 (56%) 10 (29%) 1 (20%)
OXC 0 4 (12%) 0
PHT 0 16 (47%) 0
TPM 0 0 5 (100%)
VPA 0 7 (21%) 1 (20%)
Drug loadb,d 1.3±0.6 1.8±0.7* 1.2±1.0
Differences between the risk groups were tested using a Fisher’s exact test (gender, symptomatic
epilepsy, number of different AEDs), a Mann-Whitney test (educational level, seizure frequency,
epilepsy severity score), or a student’s t-test (all remaining variables). *indicates significant differ-
ences between the low- and intermediate-risk category (p<0.05); †indicates differences between the
low- and high-risk category (p<0.05).
aLow-risk: lamotrigine (LTG), levetiracetam (LEV); Intermediate-risk: valproate (VPA), carba-
mazepine (CBZ), oxcarbazepine (OXC) and phenytoin (PHT); High-risk: topiramate (TPM)
bmean±standard deviation
cMedian (range). Scores are according to Verhage [31], range 1 (did not finish primary school) to
7 (Master’s degree)
dThe drug load is defined as the ratio of the prescribed daily dose to the defined daily dose [30].
malized clustering coefficient, and λ the normalized characteristic path length).
Only the sparsity levels within this range were considered for further analyses.
The ANCOVA test revealed significant effects of risk category on Eg at most spar-
sities within this sparsity range (Figure 4.1). Post hoc tests showed a significantly
higher Eg for patients from the low-risk category (n=14) compared with the high-
risk category (n=4), and for patients from the intermediate-risk category (n=29)
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Table 4.2. Results of the neuropsychological investigation, represented as mean±standard deviation
for each risk category.
Cognitive test results
CVST (s)a Ravenb
Risk category
Low-risk 11.5±2.9 71.7±10.3%
Intermediate-risk 15.7±6.4 73.2±10.1%
High-risk 20.2±6.7 71.7±3.1%
p-valuec 0.008 0.85
amean reaction time on the Computerized Visual Searching Task (CVST) [22]
bPercentage correct answers on the Raven Standard Progressive Matrices [24]
cTested with ANOVA
compared with the high-risk category (n=4). Eg or γ did not differ significantly be-
tween patients from the low- and intermediate-risk categories (p>0.2 at all sparsity
levels), and no significant associations were observed between γ or Eg and CVST
time (p>0.15 at all sparsity levels). Gender, epilepsy severity score, or drug load
were not significantly associated with the γ, Eg, or CVST reaction time, and the
results of these adjusted analyses were consistent with the results of the analyses
without these additional covariates (<10% change in effect size of the variable of
interest).
Discussion
The current study investigated whether patients taking AEDs with a different risk
for cognitive side effects have different functional brain topologies. To this end, we
included epilepsy patients with chronic AED treatment with different risk profiles,
i.e. a low-risk category, intermediate-risk, and high-risk category. Furthermore, we
assessed whether cognitive problems, in terms of a decreased central information
processing speed, could be associated with the functional brain organization.
A higher global efficiency was shown in patients taking TPM (n=4, the high-risk
category), compared with patients taking the low- (n=14) and intermediate-risk
AEDs (n=29). The directionality of this difference is strikingly, as this result seems
to contradict the cognitive side effects of TPM. The global efficiency is suggested
to be particularly important for more complex cognitive tasks, for which different
brain areas are involved [33]. The ‘better’ global efficiency in TPM users might
however be interpreted as a compensatory mechanism, or could be explained by
a ‘survivor effect’. As patients with side effects are more likely to switch to other
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Figure 4.1. Mean clustering coefficient (A, C) and global efficiency (B, D) for each risk category.
Both clustering coefficient and global efficiency are normalized, i.e. the measures are divided by the
clustering coefficient and global efficiency of random networks. A and B show the graph measures as a
function of sparsity, while B and D show the results at a single sparsity level. Error bars show standard
deviations, while the asterisks indicate significant differences between the risk categories (p<0.05, with
age included as covariate).
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AEDs, it is likely that these patients are less vulnerable for cognitive problems.
The higher global efficiency in the high-risk group might therefore reflect a lower
susceptibility for cognitive side effects of these patients [34, 35]. However, these
patients did have a lower processing speed compared with the other patients, which
argues against this explanation and in favor of a compensatory mechanism.
No differences in graph measures were observed between the patients groups
taking AEDs from the low- and from the intermediate-risk category. It is possible
that the effects of TPM on brain organization are more pronounced compared
with effects of other AEDs, but TPM can also have distinctive effects on brain
organization. TPM is suggested to have a unique cognitive profile, with specific
effects on verbal fluency. Moreover, it has multiple mechanisms of action, and both
these mechanisms and its chemical structure differ from other AEDs [36].
Furthermore, no associations were found between processing speed and graph
measures, in contrast to a previous study that showed not only associations between
intellectual decline and a lowered clustering coefficient in patients with epilepsy, but
also with increasing drug load [17]. The latter suggests that the intellectual decline
(which was based on intelligence tests) was a side effect of the AED treatment,
but this could also result from differences in epilepsy characteristics. That study
included more patients with a high drug load (15% of the patients had a drug load
higher than 3) than the current study (no drug loads higher than 3 in the included
patients), thus it is possible that the effects on graph measures are only measureable
in patients with higher drug loads or AEDs with high risks on cognitive complaints.
The measured information processing speed covered the whole range from nor-
mal to a clearly affected processing speed, and patients taking AEDs known to
induce cognitive side effects, showed lower processing speeds than patients with
lower risk AEDs. These results could therefore not explain the lack of associations
between graph measures and information processing speed, or the lack of differ-
ences in graph measures between the low- and intermediate-risk category. Also no
trends were shown, while the total number of participants (48), and the number of
patients in the low- (16) and intermediate-risk categories (34) were relatively large,
making it unlikely that this lack of findings were due to limited power.
All included patients in the current study were diagnosed with localization-
related epilepsy. Epilepsy is associated with a decreased global efficiency and in-
creased clustering coefficient, although some studies showed a decreased clustering
coefficient in patients with epilepsy [37]. It is therefore plausible that the functional
brain networks of all three groups of patients in this study were already altered
compared with healthy participants, irrespective of AED treatment.
This study has several limitations. Although we tried to include comparable
patient groups, the risk categories differed in age and drug load, suggesting that our
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study population is biased. Therefore, the analyses were corrected for these charac-
teristics by including age and drug load as covariates. Besides these characteristics,
also other factors could have confounded our results, such as the location of the
epileptic focus or effects of AEDs on the neurovascular coupling, which should be
assessed in separate studies [38]. Finally, no information is available about changes
over time and causality due to the cross-sectional design.
Conclusion
No differences in functional network graph measures could be detected between
patients with epilepsy after chronic use of AEDs with a different risks on cognitive
side effects. Only the four patients taking TPM, which has a high risk for developing
cognitive side effects, showed a more efficient brain network topology, which might
be a compensatory mechanism. Also no associations were found between the graph
measures and the measured cognitive impairments, specifically slowing of central
information processing. Alterations in functional brain network organization may
be only subtle and measureable in patients with more severe cognitive side effects.
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Continuous evaluation of clinical studies, improvement of existing techniques,
and explorations of novel measurement techniques are necessary to increase insights
into epilepsy and improve its treatment. In this context, a number of clinical and
methodological studies were set out in the current thesis, for which the aim was
twofold. The first aim was to identify neuronal substrates of cognitive side effects of
antiepileptic drugs (AEDs) measured with currently available magnetic resonance
(MR) techniques. The second aim was to develop and apply magnetic resonance
techniques that may give new insights in the role of neurotransmitters in epilepsy
and impaired cognition, an often occurring co-morbidity of epilepsy.
Considering the first aim, a literature review (Chapter 2) and two clinical MR
studies on patients with epilepsy were performed, assessing the associations between
AED use, cognition, and neurotransmitter concentrations (Chapter 3) or functional
brain network organization (Chapter 4). Considering the second aim, two studies
have been performed. Chapter 5 describes the results of a study performed on the
accuracy, repeatability, and concordance of two MR spectroscopy (MRS) sequences
commonly applied to measure concentrations of the neurotransmitter glutamate.
In Chapter 6, the spatial cerebral distribution of the neurotransmitters glutamate
and GABA, was investigated and the concept of neurotransmitter networks was
introduced.
Three questions relevant for these five chapters, were:
(i) How do AEDs affect the brain, and how is that related to cognitive side
effects?
(ii) How do local measurements provide information on distal effects and brain
networks?
(iii) And how valid are the advanced measurement techniques applied?
The results of the five chapters together will be discussed according to these
three questions in the following sections, ending with a general conclusion.
Cognitive side effects of antiepileptic drugs
Current findings
To identify neuronal substrates of cognitive side effects of AEDs, two different
techniques were employed: (i) MRS, that enables in vivo measurements of gluta-
mate and γ-aminobutyric acid (GABA), which are the most common excitatory
and inhibitory neurotransmitters in the brain, respectively, and (ii) functional MR
imaging (fMRI), which provides measures indicative of brain activity.
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Previous MRS studies showed that AEDs with a known GABAergic mechanism
of action, such as topiramate and vigabatrin, increased cerebral GABA concentra-
tions. Effects on glutamate concentrations were assessed by only a few studies so
far and are therefore currently not known (Chapter 2). By combining neuropsy-
chological testing with MRS, we showed that lower glutamate concentrations could
be linked to cognitive slowing in patients with epilepsy taking AEDs (Chapter 3).
At neuronal scale, AEDs are claimed to suppress (hyper) excitability. However,
at brain level fMRI studies showed that brain activity can either be decreased,
remain unaffected or can even be increased (Chapter 2). The impact of these ef-
fects were AED type dependent and also differed between various brain regions.
However, previous studies suggested that not the brain activity per se, but coordi-
nated brain activity between different brain regions, i.e. functional brain networks,
are important for cognitive functioning [1–3]. Therefore we performed a study of
these functional brain networks and AED use in relation to the existing cognitive
problems (Chapter 4). In this study, surprisingly no associations between cognitive
slowing and brain network organization were found, and only the small subgroup
of patients taking AEDs from the highest risk group (n=4) showed altered network
measures compared with patients taking AEDs from the low- or intermediate-risk
group. Based on this study, we concluded that the effect of AEDs on functional
brain network organization may be subtle and only detectable in patients with
more severe cognitive side effects.
Mechanisms of action
Currently, more than twenty different AEDs are available with different mechanisms
of action, which can be distinguished in three main mechanisms: GABAergic,
glutamatergic, and voltage-gated channels [4]. Cognitive side effects of AEDs are
likely a direct effect of these mechanisms [5]. Side effects are often dose-dependent
and occur only during the use of AEDs and disappear if AED use is discontinued.
It has been suggested that mainly GABAergic mechanisms induce cognitive side
effects, but also these effects can be caused by AEDs with other mechanisms of
action [6]. For instance, the AED phenytoin targets voltage-gated sodium channels,
but is also known to affect attention, memory and mental speed [7]. These factors
suggest that cognitive side effects are a result of attenuated neuronal activity with
AED use. The observed association between lower glutamate concentrations and
cognitive slowing supports this hypothesis, as glutamate concentrations are likely
related to excitatory activity [8]. However, specific mechanisms might attribute to
specific cognitive complaints: GABAergic mechanisms are hypothesized to affect
attention, while glutamatergic mechanisms might have a negative effect on learning
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and memory due to their interference with NMDA receptor, important in learning
and memory [6].
Methodological considerations
The distinction between cognitive problems due to epilepsy itself or due to treat-
ment is a major problem when assessing cognitive side effects of AEDs. Epilepsy is
a very heterogeneous disease, with a large variety in causes (varying from tumors
to genetic defects), affected regions in the brain, number and type of seizures, and
age of onset [9]. All these effects might affect cognition differently [10], and also the
selection of appropriate AEDs is based on some of these factors [9]. A disadvantage
of the observational nature of the studies described in this thesis is therefore the
possible confounding effects of the various characteristics of the epilepsy itself.
Another consideration about the design of the study is the distinction of the
AEDs in low, intermediate, and high-risk categories, irrespective of the mechanism
of action. This can be justified by the cognitive side effects, but the effects of
AEDs on neurotransmitter concentrations, or on functional brain organization,
might depend on the mechanism of action. More studies are therefore necessary to
assess these associations in individual AEDs.
Clinical implications and future directions
AED treatment aims to achieve seizure freedom without inducing adverse effects.
Unfortunately, this treatment is often accompanied with side effects, of which cog-
nitive problems are an important category [11]. Currently, we are neither able to
predict nor to explain which patient will suffer from side effects. More insights into
this topic might improve AED treatment in two ways: first, it might help clinical
decision-making if a neurologists knows beforehand if a patient is vulnerable to
develop cognitive side effects, and second, it might provide guidance in the search
for new AEDs with less cognitive side effects.
The associations of brain glutamate levels, AED use, and cognition described
in Chapter 3 might give rise to more focused studies to predict cognitive problems
in patients with epilepsy. For this purpose, differences in glutamate levels between
patients with and without side effects should be apparent before start of treat-
ment. Therefore it is important to assess the relationship between glutamate levels
and cognition both before and during AED treatment, preferably in longitudinal
studies.
The association of cognitive side effects with neuronal activity, should be fur-
ther assessed and specified using other techniques than MR. In vitro studies have
been used to assess effects of AED use on neuronal activity and synaptic plasticity,
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which can be related to the known side effects of AEDs [12, 13]. Electroencephalog-
raphy (EEG) can be applied to measure associations of AEDs, cognition and brain
activity patterns [14], while positron emission tomography (PET) might give addi-
tional information about receptor binding. PET tracers can be applied to measure
the affinity of receptors, such as the radiotracer 11C-flumazenil to determine the
GABAA receptor binding [15].
fMRI appears to be the most obvious MR technique to measure neuronal ac-
tivity, but has some disadvantages when studying AED effects on the brain. fMRI
measures the blood oxygenation level dependent (BOLD) activity, which is only
indirectly related to brain activity. fMRI is mostly applied to measure task-related
activation patterns. Unfortunately, the intrinsic signal responses to the task are
little and also the relative change in BOLD signal due to medication is often low,
which makes fMRI less suitable to measure global changes in activity [16]. BOLD
signals are also sensitive to possible (unwanted) effects of medication on blood flow,
and fMRI studies of AED effects should therefore be combined with techniques to
measure this blood flow, such as arterial spin labeling (ASL) [16].
Local measurements, distal effects, and brain networks
Current findings
A common theme in this thesis is the connection between local measurements and
distal effects, and between local measurements and brain networks. Two questions
that frequently arose are:
(i) Does a local finding also reflect distal abnormalities?
(ii) Are characteristics of single regions related to characteristics of other or even
global regions?
With MRS, the voxel-of-interest is often placed occipitally, because the high-
est signal quality can be obtained in that region [17, 18]. This was also the case
in Chapter 3, while in this study, the measured glutamate concentrations were
associated with information processing speed, a cognitive function that strongly
involves the prefrontal cortex [19]. An unanswered question is how these occipi-
tal measurements are associated with functions that involve the prefrontal brain
regions.
Chapter 6 presents a study that attempts to extend from local MRS mea-
surements to global brain networks. Glutamate and GABA concentrations were
measured in 21 distributed brain areas, and connections between these areas were
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computed and analyzed. While these neurotransmitter concentrations showed cor-
relations between several distant regions, this correlation was absent between other
regions, i.e. we could speak of large-scale spatial organization, so-called networks,
for both neurotransmitters. We furthermore measured a higher neurotransmitter
connectivity in patients with epilepsy than in healthy participants.
Conceptual background
We assumed that areas that share characteristics, are likely to be connected some-
how, a phenomenon known as the ‘homophily principle’ in social sciences [20]. For
two connected areas, the neurotransmitter concentration in one area is positively or
negatively associated with the other area [21]. The meaning of these correlations,
and mechanisms causing these correlations, are currently unknown, but are likely
related to an underlying functional organization of concerted brain activity. While
glutamate can be related to excitatory activity, GABA concentrations are related to
the fraction of GABAergic neurons [8]. Concentrations of both neurotransmitters
have previously been associated with functional connectivity [22]. It is plausible,
that areas with shared functionality, show correlated activity, and therefore reveal
correlations in neurotransmitter concentrations underlying this activity.
This network concept could explain the association between occipital gluta-
mate concentrations and prefrontal functions, as the glutamate network described
in Chapter 6 indeed showed connections between the occipital grey matter and pre-
frontal white matter. In this scenario, AEDs have a prefrontal effect, and due to
that effect the occipital glutamate concentrations are altered, or vice versa: AEDs
alter occipital glutamate levels, which affect prefrontal areas, that in its turn affects
cognition.
However, as the location of the epileptic focus is not an important factor in the
decision of an appropriate AED [9], we can speculate that AEDs have a similar
effect on all brain areas. Thus, in our study, an alternative possibility is that the
occipital changes in glutamate concentrations reflect global changes.
Methodological considerations
As the study of neurotransmitter networks is a first exploration of this concept,
there are several methodological considerations, partly due to scanning difficulties
(coarse spatial resolution, long scanning time, scanning artifacts, etc.) and partly
as result of the analyses (e.g. how to compensate for differences in grey and white
matter content). A major drawback is that at this moment, the networks are formu-
lated at group level instead of individual level. Alternative methods are therefore
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required to associate individual clinical measures, such as seizure frequency, drug
load or cognitive co-morbidity, to neurotransmitter networks.
As already mentioned, the precise mechanisms underlying the neurotransmitter
connections are unknown, and the method provides no actual physical connections,
but an implied connection through neuronal correlations of neurotransmitters. Un-
fortunately, all methods to study in vivo brain networks use indirect measures for
connections. However, each modality provides unique information about brain
functioning, thus the most complete information can be obtained by combining
measurements from all different modalities [23].
Clinical implications and future directions
The neurotransmitter connectivity appeared to be higher in patients with epilepsy
than healthy participants. Epilepsy is a disease in which large-scale cortical net-
works are disrupted. Crucial for these networks are inhibitory neurons, synaptic
transmission, and neuronal properties [9]. Neurotransmitter networks might be able
to give additional information about network dysfunction in epilepsy, as GABA and
glutamate concentrations reflect inhibitory neurons and neuronal activity. Future
studies might focus on the relation between AED use and neurotransmitter net-
work alterations, because some AEDs alter GABA concentrations (Chapter 2) and
cognitive problems were related to glutamate concentrations (Chapter 3). Finally,
neurotransmitter network dysfunction might be related to cognitive problems in
epilepsy. Studying neurotransmitter networks might therefore help to understand
and manipulate the cortical networks in epilepsy (for instance with AEDs), but
also in other neurological and psychiatric diseases [24].
Also single-voxel MRS studies might benefit from knowledge of neurotransmit-
ter networks. Neurotransmitter and other neurometabolite concentrations are com-
monly measured in occipital regions, while the results are associated with cognitive
functions [25–27]. Information about the coherence between these neurometabolite
concentrations in different brain regions, both in healthy participants and patients,
might contribute to the interpretation of these studies.
Validation of MR techniques
Overview thesis
Before novel techniques can be used for clinical or research purposes, validation of
these techniques is necessary. For this thesis, we can distinguish two aspects that
need validation: firstly, the applied acquisition techniques, i.e. can MRS measure
the correct metabolites and concentrations, and can fMRI correctly detect brain
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activation? And secondly, the applied analyses methods need validation, especially
when discussing brain connectivity.
MR spectroscopy (as applied in Chapter 3) is a commonly used technique
to measure in vivo neurotransmitter concentrations. The validity of the applied
method to measure glutamate concentrations was further assessed in Chapter 5.
This chapter presents a study to compare two commonly applied sequences (PRESS
and MEGA-PRESS) that enable in vivo glutamate concentrations. The results
showed that, although both PRESS as MEGA-PRESS had a sufficient accuracy
(in phantoms) and in vivo reproducibility, the in vivo concordance between those
sequences was lower than expected. The cause of this low concordance is currently
unknown, as both methods could be applied to measure glutamate concentrations.
Future studies interested in glutamate measurements, might choose between these
two commonly used and easily to implement sequences. While PRESS has a shorter
duration and better repeatability than MEGA-PRESS, MEGA-PRESS enables also
GABA measurements. Studies interested in both GABA and glutamate, with a
limited time, might therefore choose to only perform a MEGA-PRESS scan.
A neurotransmitter network, described in Chapter 6, is a newly introduced con-
cept. As only a correlation on group level is presented, and no individual network
measures, no reproducibility measures of network measures could be presented.
However, five participants were measured twice, and the results were robust for
these within-subjects variations. Measurements of neurotransmitter concentrations
showed a moderate to good reproducibility for these participants.
Implications and directions for further studies
At this moment, the study of neurotransmitter networks is still in its infancy.
Methodological improvements and necessary validation are required before the
measurement of neurotransmitter networks can be applied in daily clinical practice.
Therefore, neurotransmitter networks should be further validated in research stud-
ies, starting with repeating the current study which larger sample sizes to confirm
the current findings.
Further validation of functional brain network analyses was out of the scope
of this thesis. However, several arbitrary choices have to be made during this
analyses, which can largely affect the result of the study, such as the handling of
negative weighted connections [28]. The results described in Chapter 4 differ from
those of a previous study, which did find associations between functional brain
network organization, AED use (i.e. drug load) and cognitive functioning (IQ) [29].
This latter study included patients with higher drug loads, thus these patients
might have suffered from more severe side effects. However, this difference might
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also result from differences in analyses methods. Further evaluation of different
analyses methods for functional networks is therefore required, and differences in
these methods between studies should be considered if comparing these studies.
Conclusion
The studies described in this thesis aimed to identify neuronal substrates of cog-
nitive side effects of AEDs, and to study novel MR techniques that may give new
insights on the neurotransmitter function in epilepsy and cognition. The demon-
strated associations of glutamate concentrations, AED use, and cognition might be
suitable as biomarker for cognitive side effects of AED treatment. Two different
sequences to measure these glutamate concentrations (i.e. PRESS and MEGA-
PRESS) were studied, and the results showed that both sequences can be employed
to measure in vivo glutamate concentrations. Finally, the concept of neurotrans-
mitter networks was introduced, which provides a new dimension to further study
associations of epilepsy, AED use and cognition.
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Summary
Epilepsy is a neurological disease which is characterized by unprovoked recurrent
seizures, during which the brain shows abnormal and excessive neuronal activity.
The majority of the patients use antiepileptic drugs (AEDs) to suppress epileptic
seizures. Unfortunately, these AEDs also induce adverse effects, such as cognitive
problems.
The brain can be considered as a network, encompassing neurons which are
connected via synapses. It is assumed that the integrity of brain networks is im-
portant for cognitive functioning, and that this integrity is affected in neurological
diseases as epilepsy. Different magnetic resonance (MR) techniques can be em-
ployed to assess different aspects of brain connectivity: functional MR imaging
(fMRI) enables the assessment of functional brain networks, i.e. the framework
of all, functionally connected brain areas, while MR spectroscopy (MRS) enables
measurements of the neurotransmitters GABA and glutamate, the most abundant
inhibitory and excitatory neurotransmitters in the brain, respectively. The aim
of this thesis, as described in Chapter 1, was to further assess the associations
between brain connectivity and cognitive problems in epilepsy.
In Chapter 2, an overview is given of previous MR studies that assessed effects
of AEDs on the brain. MRS studies showed that AEDs with GABAergic mecha-
nisms of action (such as topiramate and vigabatrin) increase the cerebral GABA
concentrations. Effects on glutamate concentrations were thus far less frequently
assessed and therefore not known conclusively. Chapter 2 also discussed fMRI
studies of AED effects. Although at neuronal level, AEDs aim to suppress (hy-
per) excitability, fMRI studies showed that at the brain level, brain activity can
be decreased, but also unaffected or even increased. The effects of AEDs on brain
activity differed between AED-type and brain regions.
Chapter 3 and 4 describe two studies that assessed associations between
AEDs, cognitive problems, and in vivo neurotransmitter levels or brain network
organization, respectively. For these studies, three groups of patients on chronic
AED treatment were included: One group using AEDs with a low risk for cognitive
side effects (lamotrigine or levetiracetam, n=16), one group using AEDs with an in-
termediate risk for cognitive side effects (carbamazepine, oxcarbazepine, phenytoin
or valproate, n=34), and a group using AEDs with a high risk for cognitive side
effects (topiramate, n=5). All patients underwent cognitive testing and MR scan-
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ning. The Visual Computerized Searching Task (CVST) was applied to measure
complex information processing speed, which is often affected by AED use. MRS
was performed to measure in vivo neurotransmitter levels, and the brain network
organization was measured using resting-state fMRI.
The associations between AEDs, cognitive problems, and neurotransmitter lev-
els are described in Chapter 3. Patients with decreased processing speeds showed
lower glutamate concentrations than patients with a normal processing speed. Fur-
thermore, the glutamate concentrations were also significantly lower in the high
and intermediate-risk category than in the low-risk category. No significant as-
sociations were found between GABA and information processing speed or risk
category. Based on this study, we concluded that lower glutamate concentrations
are related to AED use and slow down central information processing in patients
with epilepsy.
Chapter 4 describes associations between AEDs, cognition, and functional
brain network measures. Two measures were described: the clustering coefficient
and the global efficiency, which are measures for functional segregation and integra-
tion, respectively. No associations were observed between information processing
speed and these brain network measures, and only the high-risk category showed
an increased global efficiency, which might be due to compensatory mechanisms.
Alterations in functional brain network organization may be only subtle in the pa-
tients studied and may become measureable in patients with more severe cognitive
side effects.
For further evaluation, MR techniques were studied that may give new insights
in epilepsy and cognition. Chapter 5 presents a study that evaluated different
MRS methods to measure glutamate levels. Although not specifically designed for
this purpose, PRESS and MEGA-PRESS sequences are both often used to measure
glutamate. PRESS is a commonly applied method to measure neurometabolites,
but is not able to measure GABA concentrations, while MEGA-PRESS allows for
quantification of GABA. Chapter 5 compares the accuracy, repeatability, and
concordance of these sequences. Phantom experiments showed a good accuracy
for both sequences. The repeatability was tested in five healthy participants and
was sufficient in both sequences, but was better in PRESS than in MEGA-PRESS.
However, the concordance between the sequences was only moderate (r=0.4), which
might be due to macromolecule contamination in the PRESS or MEGA-PRESS
spectra. Based on this study, we concluded that MEGA-PRESS can be used to
combine GABA and glutamate measurements, albeit at a cost of lower repeatability
compared with PRESS.
Chapter 6 describes a new method to assess brain networks based on metabolic
information, in particular glutamate, GABA, and N-acetylaspartate measurements.
i
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Many clinical neuroimaging studies are focused on altered structural or functional
brain connectivity. However, these studies cannot provide direct information on
the defective neurons or the linked neurotransmitter disbalance, which underlies
abnormal neuronal activity. Therefore, the concept of ‘neurotransmitter networks’
was introduced. Areas were considered connected if the Pearson’s correlation co-
efficient was significant between those areas, across the participants.
This concept was tested in fifteen healthy participants and ten patients with
cryptogenic localization related epilepsy. In the healthy participants, 21%, 19%,
and 26% of the possible connected areas showed a significant correlation for gluta-
mate, GABA, and NAA, respectively. These connections can be conceptualized as
‘metabolic brain networks’. When comparing networks from patients with epilepsy
to those from healthy participants, an increased glutamate and GABA connectivity
was found in the epilepsy group. We concluded that these neurotransmitter net-
works, and the increased neurotransmitter connectivity in patients with epilepsy,
should be further explored to increase insights into epilepsy.
This thesis is finished with a general discussion in Chapter 7. This chapter
provides a general overview of the main findings in this thesis, discusses these find-
ings in a broader perspective and provides recommendations for further research.
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Samenvatting
Epilepsie is een neurologische aandoening die gekarakteriseerd wordt door niet-
uitgelokte, herhaald optredende aanvallen. Tijdens deze aanvallen vertoont het
brein abnormale excessieve neuronale activiteit. De meerderheid van de patie¨nten
gebruikt anti-epileptica om epileptische aanvallen te onderdrukken. Deze medicatie
zorgt echter ook voor bijwerkingen, waaronder cognitieve problemen.
Het brein kan worden gezien als een netwerk bestaande uit neuronen die ver-
bonden zijn via synapsen. Er wordt aangenomen dat de integriteit van dit hersen-
netwerk belangrijk is voor het cognitief functioneren, maar afwijkend is als sprake
is van epilepsie. Verschillende magnetische resonantietechnieken zijn beschikbaar
om de hersennetwerken te onderzoeken: functionele magnetische resonantie ima-
ging (fMRI) maakt het mogelijk om functionele hersennetwerken te onderzoeken,
terwijl met magnetische resonantie spectroscopie (MRS) de concentraties van de
meest voorkomende activerende en remmende neurotransmitters in het brein (glu-
tamaat en GABA) gemeten kunnen worden. Het doel van dit proefschrift, zoals
beschreven in hoofdstuk 1, was om de samenhang tussen hersenconnectiviteit en
cognitieve problemen als gevolg van epilepsie verder te onderzoeken.
Hoofdstuk 2 geeft een overzicht van eerdere MR studies die effecten van anti-
epileptica op het brein hebben onderzocht. MRS studies hebben aangetoond dat
anti-epileptica met GABAerge werkingsmechanismen (zoals topiramaat en viga-
batrine) de GABA-concentraties in het brein verhogen. Het effect op glutamaat-
concentraties is minder vaak onderzocht en daardoor niet duidelijk. Ook fMRI
studies naar effecten van anti-epileptica op het brein worden besproken in hoofd-
stuk 2. Op celniveau hebben anti-epileptica als doel de (hyper)excitabiliteit te
onderdrukken. Echter, fMRI studies hebben aangetoond dat op breinniveau, anti-
epileptica hersenactiviteit kunnen onderdrukken, maar ook onaangedaan laten of
zelfs stimuleren. De precieze effecten van anti-epileptica op de hersenactiviteit
verschilden per type anti-epilepticum en hersengebied.
Hoofdstuk 3 en 4 beschrijven twee studies waarin de samenhang tussen lang-
durig gebruik van anti-epileptica, cognitieve problemen, en in vivo neurotransmit-
terconcentraties op hersennetwerkorganisatie onderzocht is. Voor deze studies zijn
drie groepen epilepsiepatie¨nten ge¨ıncludeerd: De eerste groep bestond uit patie¨nten
die anti-epileptica gebruiken met een laag risico op bijwerkingen (lamotrigine of le-
vetiracetam, n = 16). De tweede groep bestond uit patie¨nten die anti-epileptica
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gebruiken met een gemiddeld risico op cognitieve bijwerkingen (carbamazepine,
fenyto¨ıne, oxcarbazepine of valproaat, n=34), terwijl de derde groep bestond uit
patie¨nten die anti-epileptica gebruiken met een hoog risico op cognitieve bijwerkin-
gen (topiramaat, n=5). Alle patie¨nten ondergingen cognitieve testen en een MR
scan. De Computerized Visual Searching Task (CVST) is gebruikt om de verwer-
kingssnelheid van complexe informatie te meten, een cognitieve functie die vaak is
aangedaan door anti-epileptica. Neurotransmitterconcentraties zijn gemeten met
behulp van MRS, en de organisatie van de hersennetwerken in rust zijn met behulp
van fMRI gemeten.
De samenhang tussen anti-epileptica, cognitieve problemen, en neurotransmit-
terconcentraties wordt beschreven in hoofdstuk 3. De glutamaatconcentratie
bleek positief gecorreleerd met de informatieverwerkingssnelheid. Met andere woor-
den, patie¨nten met een lagere informatiesnelheid, hadden ook een lagere gluta-
maatconcentratie. Verder was deze concentratie significant lager in de patie¨nten
die medicatie met een hoog of gemiddeld risico op bijwerkingen gebruikten, dan in
de patie¨nten die medicatie met een laag risico op bijwerkingen gebruikten. Tus-
sen de GABA-concentratie en informatieverwerkingssnelheid, of tussen de GABA-
concentratie en risicocategorie, waren geen significante associaties. Gebaseerd op
deze resultaten concludeerden we dat lagere glutamaatconcentraties gerelateerd
zijn aan het gebruik van anti-epileptica en een vertraagde informatieverwerking in
epilepsiepatie¨nten.
Hoofdstuk 4 beschrijft de samenhang tussen anti-epileptica, cognitie, en brein-
netwerkmaten. Twee verschillende maten werden beschreven: de clustercoe¨fficie¨nt
en de globale efficie¨ntie, welke maten zijn voor de respectievelijke functionele se-
gregatie en integratie. Er werden geen associaties geobserveerd tussen informatie-
verwerkingssnelheid en deze netwerkmaten. Wel liet de hoog-risicogroep een signi-
ficant hogere globale efficie¨ntie zien dan de laag- en gemiddeld-risicogroepen, wat
mogelijk het gevolg is van een compensatiemechanisme. Wijzigingen in functionele
hersennetwerkorganisatie zijn mogelijk subtiel en alleen meetbaar in patie¨nten met
ernstigere cognitieve bijwerkingen.
Het tweede deel van dit proefschrift bevat studies waarin MR technieken zijn
onderzocht die mogelijk nieuwe inzichten in epilepsie en cognitie kunnen geven.
Hoofdstuk 5 beschrijft een studie waarin verschillende MRS methoden om gluta-
maatconcentraties te meten werden vergeleken. De sequenties PRESS en MEGA-
PRESS worden beide vaak gebruikt om glutamaatconcentraties te meten, hoewel
ze hier niet speciaal ontworpen voor zijn: PRESS wordt veel gebruikt om verschil-
lende neurometabolietconcentraties te meten, maar kan geen GABA-concentraties
meten. MEGA-PRESS is juist ontworpen om deze GABA-concentraties te me-
ten. Hoofdstuk 5 vergelijkt de accuraatheid, reproduceerbaarheid, en overeen-
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stemming van glutamaatmetingen met deze sequenties. Fantoommetingen lieten
een goede accuraatheid voor beide sequenties zien. De reproduceerbaarheid is
getest in vijf gezonde proefpersonen, en bleek toereikend voor beide sequenties,
hoewel beter voor PRESS dan MEGA-PRESS. De overeenkomst tussen PRESS
en MEGA-PRESS was echter matig (r=0.4), wat mogelijk verklaard kan worden
door de aanwezigheid van macromoleculen in het PRESS of MEGA-PRESS spec-
trum. Gebaseerd op deze studie concludeerden we dat MEGA-PRESS inderdaad
gebruikt kan worden om GABA en glutamaatmetingen te combineren, hoewel met
een lagere reproduceerbaarheid dan wanneer PRESS gebruikt zou kunnen worden.
Hoofdstuk 6 beschrijft een nieuwe methode om hersennetwerken te onder-
zoeken, gebaseerd op metabole informatie verkregen uit glutamaat, GABA, en
N-acetylaspartaat metingen. Klinische studies bestuderen voornamelijk structu-
rele en functionele breinnetwerken. Echter, hiermee wordt geen directe informatie
over neuronale integriteit of neurotransmitterbalans verkregen, wat de oorzaak is
van abnormale neuronale activiteit in epilepsie. Daarom introduceerden wij het
‘neurotransmitternetwerk’ concept. Gebieden in de hersenen werden verondersteld
verbonden te zijn, als de correlatie tussen deze gebieden (gezien over de proefper-
sonen) significant was.
Dit concept is getest in vijftien gezonde proefpersonen en tien patie¨nten met
cryptogene, lokalisatie-gebonden epilepsie. In de gezonde proefpersonen liet 21%,
19% en 26% van de mogelijke verbindingen een significante correlatie voor res-
pectievelijk glutamaat, GABA en NAA zien. Deze verbindingen kunnen worden
gezien als een ‘metabool breinnetwerk’. Zowel de glutamaat, als de GABA net-
werken van de epilepsiepatie¨nten hadden een hogere connectiviteit dan die van de
gezonde proefpersonen. We concludeerden dat deze neurotransmitternetwerken en
verhoogde neurotransmitterconnectiviteit in epilepsiepatie¨nten verder onderzocht
zouden moeten worden om de kennis over epilepsie te vergroten.
Het proefschrift wordt afgesloten met een algemene discussie in hoofdstuk 7.
Dit hoofdstuk geeft een overzicht van de belangrijkste bevindingen in dit proef-
schrift, bediscussieert de bevindingen in een breder geheel en geeft aanbevelingen
voor vervolgonderzoek.
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Valorization
Relevance
Thousands of MR studies have been performed to investigate functional brain net-
works and neurotransmitter concentrations. These studies are primarily performed
in the fields of neurology, neurosciences and psychology. Two different aims can be
distinguished in these studies: firstly, to increase the understanding of healthy or
diseased brain functioning; and secondly, to detect biomarkers that might be used
for diagnosis, to predict disease progression or treatment effects [1–3].
In this thesis, we focused on brain connectivity in epilepsy, and its relation
to cognition. In the Netherlands, there are approximately 120,000 patients with
epilepsy, and six-thousand new patients are diagnosed every year [4]. Epilepsy is
often accompanied with cognitive problems, such as impaired memory, concentra-
tion, or slowed information processing speed [5]. These cognitive problems may be
caused by the epilepsy itself, the underlying etiology, or as side effect of antiepilep-
tic drug (AED) treatment. At this moment, neurologists have no objective means
to predict who will develop adverse side effects or not.
We mainly focused on the effects AED treatment in this thesis. Cognitive side
effects are among the least tolerated side effects for patients with epilepsy [6], and
are an important reason to halt or change the AED treatment [7]. Besides a large
burden for the patients, cognitive side effects are also accompanied with economic
costs, including increased health care costs, productivity losses, and patients and
family costs. The total societal costs of cognitive side effects are estimated to be
around 7,000e per patient per year in the Netherlands [8]. Better understanding
of the relation between epilepsy, AED treatment, and cognition might help during
clinical decision-making and ultimately improve treatment of patients with epilepsy.
Main findings
In the first part of this thesis, clinical studies are presented that assessed associ-
ations between AED use, cognition, and MR markers. We observed associations
between decreased information processing speed and lower glutamate concentra-
tions. These glutamate concentrations were also associated with AED use. The
second part of this thesis described methodological studies to neurotransmitter
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measurements. We compared two methods to measure in vivo glutamate concen-
trations using MR spectroscopy: PRESS and MEGA-PRESS. This study showed a
good accuracy for both methods, although the repeatability was better in PRESS
than MEGA-PRESS. Finally, we developed a method to assess ‘neurotransmitter
networks’, and showed an increased glutamate and GABA connectivity in patients
with epilepsy.
Target groups
First of all, the findings of this study are relevant for patients with epilepsy, as
the findings might, in future, improve pharmacological treatment in epilepsy. This
is also of interest for their neurologist, who might be better able to select proper
treatment, and the pharmaceutical industry. Pharmaceutical applications of MRI
are starting to develop, and MR markers might be beneficial to capture cogni-
tive side effects or treatment efficacy in an early state, or to explore proper dose
ranges [9].
The methodological part is mostly relevant for other researchers in the field
of neurology, neurosciences and psychology, as it might aid new studies of the
involvement of neurotransmitter levels in different neurological, psychological and
psychiatric diseases. Therefore, other patients suffering from these diseases might
benefit from these studies as well.
Innovation and future directions
The studies presented in this thesis should be considered as explorations on the
interplay of MR methods and epilepsy, AED treatment, and cognition. While
advanced MR imaging of epilepsy and its consequences is an emerging field, MR
studies to study AED effects are relatively scarce and to our knowledge, the studies
in this thesis are the first that associate AED use and cognitive functioning to re-
spectively neurotransmitter levels and functional brain organization. The observed
associations between glutamate levels and cognitive function might be useful as
biomarker to predict which patient will suffer from cognitive side effects, and who
will not. However, it is currently not known whether the differences in glutamate
levels precede the cognitive problems or coincide with these problems. Therefore,
longitudinal studies to this topic are required.
The main objective of the comparison between PRESS and MEGA-PRESS
was to aid future clinical studies aiming to measure glutamate concentrations. In
our study, we applied both PRESS, to measure glutamate concentrations, and
MEGA-PRESS, to measure GABA concentrations. We showed that the glutamate
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concentration could also be measured with MEGA-PRESS; comparable studies
might therefore choose to only apply a MEGA-PRESS scan, and thereby shortening
the scanning time.
Neurotransmitter networks, described in Chapter 6, are a newly introduced
concept and might provide new possibilities to study brain function. Future studies
should aim at a further evaluation of this concept. Optimization is still possible
at the acquisition and the analysis stage of the data. Furthermore, the concept
should be tested in larger groups and in different populations, such as children or
elderly, or in different brain diseases.
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Dankwoord
Zoals gebruikelijk wil ik in dit laatste hoofdstuk iedereen die heeft bijgedragen
aan dit proefschrift bedanken. Sommigen hebben hele concrete bijdragen geleverd.
Anderen stonden meer op de achtergrond, maar ook zonder hen had ik dit niet
kunnen afronden.
Allereerst wil ik graag mijn promotieteam bedanken. Walter Backes, Bert Al-
denkamp en Jaap Jansen, bedankt dat jullie mij de mogelijkheid hebben geboden
voor dit promotieonderzoek, en voor jullie altijd betrokken en toegankelijke bege-
leiding. Dit heb ik als zeer prettig ervaren.
Walter, jouw feedback kwam meestal erg snel, soms zelfs sneller dan ik eigenlijk
zou willen. Wat een luxe! Tegelijkertijd ben je altijd kritisch, maar ook erg be-
trokken bij jouw promovendi, wat volgens mij een goede promotor kenmerkt. Bert,
jouw bijdrage was wat meer op de achtergrond, maar jouw ideee¨n over en de feed-
back op met name de klinische onderdelen zijn een grote bijdrage geweest aan dit
proefschrift. Jaap, jouw deur stond altijd open en dit heb ik zeer op prijs gesteld.
Je weet een kritische blik te combineren met een pragmatische aanpak. Dit laatste
was voor mij soms wat wennen, maar daarmee ook erg leerzaam. Bedankt voor
deze samenwerking!
Verder ben ik dank verschuldigd aan al mijn co-auteurs. Allereerst mijn dank
aan Dominique: Wat heb jij hard gewerkt aan de AED studie! Ik heb bewondering
voor jouw niet-aflatende energie en wil je veel succes wensen met jouw carrie`re.
Rob Rouhl en Marielle Vlooswijk: Tien geschikte proefpersonen vinden bleek heel
lastig te zijn, maar het is op het nippertje toch gelukt! Bedankt daarvoor, en
zeker ook voor jullie kritische inbreng tijdens het onderzoek en schrijven van het
artikel. Ook Paul Hofman, Richard Lazeron, Anton de Louw, Frank van Bussel,
Tom Scheenen en Dennis Klomp dank ik voor hun inbreng. Finally, I would like
to thank Richard Edden, Nick Puts, and Desmond Tse for their contribution as
co-author.
Ook anderen hebben een essentie¨le bijdrage geleverd aan mijn onderzoek: Al-
lereerst natuurlijk alle proefpersonen die hieraan meegewerkt hebben. Verder wil ik
Remco Berting bedanken voor het scannen bij Kempenhaeghe, en Esther Steijvers
en Lotty Huijboom voor het scannen bij Scannexus. Bedankt voor alle gezellige uur-
tjes achter de scanner! Voor het maken van de fantomen moet ik Ingrid Dijkgraaf
en haar collega’s bedanken, voor het beschikbaar stellen van hun labfaciliteiten.
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Als laatste ben ik Jos en Marc veel dank verschuldigd voor alle computerfacilitei-
ten binnen de afdeling Radiologie, zonder welke ik niet alle analyses had kunnen
uitvoeren.
Daarnaast wil ik mijn kamergenoten en collega’s bedanken: Rene´, voor het hel-
pen aan het begin van mijn promotie; Frank, Harm en May voor al jullie advies e´n
de gezellige uurtjes; en Gerald, Laura, Lisanne en Joost, bedankt voor de gezellig-
heid, en succes tijdens jullie verdere promoties/postdoc-periode! Als laatste wil ik
al mijn overige collega’s bij de afdeling Radiologie en bij Kempenhaeghe bedanken
voor hun gezelligheid tijdens de lunch, borrels en de Kempenhaeghe-etentjes.
Ook een kort woord van dank aan mijn paranimfen May en Ingeborg. Waar
ik bijna mijn gehele promotietijd een kamer met May heb gedeeld, heb ik tijdens
vrijwel mijn hele studie samen met Ingeborg in e´e´n huis gewoond. Wat heb ik veel
gezelligheid, maar ook frustraties met jullie kunnen delen: niet alleen over onze
promoties, maar ook over alle andere dingen in ons leven. Fijn dat jullie naast mij
willen staan tijdens mijn verdediging!
Mijn laatste woorden zijn voor de mensen die het dichtst bij mij staan. Papa
en mama, hoewel jullie hadden gehoopt dat ik na mijn studie weer wat dichterbij
zou komen wonen, hebben jullie mij altijd gesteund en aangemoedigd om te gaan
promoveren in Maastricht. Bedankt dat jullie er altijd voor mij zijn. Lieve Fokke,
we hadden nog maar net een relatie toen ik solliciteerde voor deze promotie. Mijn
keuze om naar Maastricht te gaan heeft het ook voor jou niet makkelijker gemaakt,
maar we hebben ons samen door de vele treinreizen heen geslagen. En hoewel voor
ons beiden het ‘Hora est’ nog moet komen, durf ik al wel te stellen dat het ons
gelukt is! Dank je wel!
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